id	sid	tid	token	lemma	pos
ajlm-1282	1	1	introduction	introduction	NOUN
ajlm-1282	1	2	covid-19	covid-19	PROPN
ajlm-1282	1	3	and	and	CCONJ
ajlm-1282	1	4	cytokine	cytokine	VERB
ajlm-1282	1	5	storm	storm	NOUN
ajlm-1282	1	6	covid-19	covid-19	PROPN
ajlm-1282	1	7	and	and	CCONJ
ajlm-1282	1	8	t	t	PROPN
ajlm-1282	1	9	cell	cell	NOUN
ajlm-1282	1	10	impairment	impairment	NOUN
ajlm-1282	1	11	covid-19	covid-19	PROPN
ajlm-1282	1	12	and	and	CCONJ
ajlm-1282	1	13	immunological	immunological	ADJ
ajlm-1282	1	14	investigations	investigation	NOUN
ajlm-1282	1	15	acknowledgements	acknowledgement	NOUN
ajlm-1282	1	16	references	reference	NOUN
ajlm-1282	1	17	about	about	ADP
ajlm-1282	1	18	the	the	DET
ajlm-1282	1	19	author(s	author(s	NOUN
ajlm-1282	1	20	)	)	PUNCT
ajlm-1282	1	21	brahim	brahim	PROPN
ajlm-1282	1	22	admou	admou	PROPN
ajlm-1282	1	23	center	center	NOUN
ajlm-1282	1	24	of	of	ADP
ajlm-1282	1	25	clinical	clinical	ADJ
ajlm-1282	1	26	research	research	NOUN
ajlm-1282	1	27	,	,	PUNCT
ajlm-1282	1	28	faculty	faculty	NOUN
ajlm-1282	1	29	of	of	ADP
ajlm-1282	1	30	medicine	medicine	NOUN
ajlm-1282	1	31	and	and	CCONJ
ajlm-1282	1	32	pharmacy	pharmacy	NOUN
ajlm-1282	1	33	,	,	PUNCT
ajlm-1282	1	34	mohamed	mohamed	PROPN
ajlm-1282	1	35	vi	vi	PROPN
ajlm-1282	1	36	university	university	PROPN
ajlm-1282	1	37	hospital	hospital	NOUN
ajlm-1282	1	38	,	,	PUNCT
ajlm-1282	1	39	cadi	cadi	NOUN
ajlm-1282	1	40	ayyad	ayyad	PROPN
ajlm-1282	1	41	university	university	PROPN
ajlm-1282	1	42	,	,	PUNCT
ajlm-1282	1	43	marrakech	marrakech	NOUN
ajlm-1282	1	44	,	,	PUNCT
ajlm-1282	1	45	morocco	morocco	PROPN
ajlm-1282	1	46	abdelhamid	abdelhamid	PROPN
ajlm-1282	1	47	hachimi	hachimi	PROPN
ajlm-1282	1	48	department	department	PROPN
ajlm-1282	1	49	of	of	ADP
ajlm-1282	1	50	intensive	intensive	ADJ
ajlm-1282	1	51	care	care	NOUN
ajlm-1282	1	52	,	,	PUNCT
ajlm-1282	1	53	faculty	faculty	NOUN
ajlm-1282	1	54	of	of	ADP
ajlm-1282	1	55	medicine	medicine	NOUN
ajlm-1282	1	56	and	and	CCONJ
ajlm-1282	1	57	pharmacy	pharmacy	NOUN
ajlm-1282	1	58	,	,	PUNCT
ajlm-1282	1	59	mohamed	mohamed	PROPN
ajlm-1282	1	60	vi	vi	PROPN
ajlm-1282	1	61	university	university	PROPN
ajlm-1282	1	62	hospital	hospital	NOUN
ajlm-1282	1	63	,	,	PUNCT
ajlm-1282	1	64	cadi	cadi	NOUN
ajlm-1282	1	65	ayyad	ayyad	PROPN
ajlm-1282	1	66	university	university	PROPN
ajlm-1282	1	67	,	,	PUNCT
ajlm-1282	1	68	marrakech	marrakech	NOUN
ajlm-1282	1	69	,	,	PUNCT
ajlm-1282	1	70	morocco	morocco	PROPN
ajlm-1282	1	71	mohamed	mohamed	PROPN
ajlm-1282	1	72	abdenasser	abdenasser	PROPN
ajlm-1282	1	73	samkaoui	samkaoui	PROPN
ajlm-1282	1	74	department	department	PROPN
ajlm-1282	1	75	of	of	ADP
ajlm-1282	1	76	anesthesiology	anesthesiology	NOUN
ajlm-1282	1	77	and	and	CCONJ
ajlm-1282	1	78	intensive	intensive	ADJ
ajlm-1282	1	79	care	care	NOUN
ajlm-1282	1	80	,	,	PUNCT
ajlm-1282	1	81	faculty	faculty	NOUN
ajlm-1282	1	82	of	of	ADP
ajlm-1282	1	83	medicine	medicine	NOUN
ajlm-1282	1	84	and	and	CCONJ
ajlm-1282	1	85	pharmacy	pharmacy	NOUN
ajlm-1282	1	86	,	,	PUNCT
ajlm-1282	1	87	mohamed	mohamed	PROPN
ajlm-1282	1	88	vi	vi	PROPN
ajlm-1282	1	89	university	university	PROPN
ajlm-1282	1	90	hospital	hospital	NOUN
ajlm-1282	1	91	,	,	PUNCT
ajlm-1282	1	92	cadi	cadi	NOUN
ajlm-1282	1	93	ayyad	ayyad	PROPN
ajlm-1282	1	94	university	university	PROPN
ajlm-1282	1	95	,	,	PUNCT
ajlm-1282	1	96	marrakech	marrakech	NOUN
ajlm-1282	1	97	,	,	PUNCT
ajlm-1282	1	98	morocco	morocco	PROPN
ajlm-1282	1	99	citation	citation	PROPN
ajlm-1282	1	100	admou	admou	PROPN
ajlm-1282	1	101	b	b	PROPN
ajlm-1282	1	102	,	,	PUNCT
ajlm-1282	1	103	hachimi	hachimi	PROPN
ajlm-1282	1	104	a	a	NOUN
ajlm-1282	1	105	,	,	PUNCT
ajlm-1282	1	106	samkaoui	samkaoui	NOUN
ajlm-1282	1	107	ma	ma	PROPN
ajlm-1282	1	108	.	.	PROPN
ajlm-1282	2	1	how	how	SCONJ
ajlm-1282	2	2	can	can	AUX
ajlm-1282	2	3	clinical	clinical	VERB
ajlm-1282	2	4	immunology	immunology	NOUN
ajlm-1282	2	5	laboratories	laboratory	NOUN
ajlm-1282	2	6	contribute	contribute	VERB
ajlm-1282	2	7	to	to	ADP
ajlm-1282	2	8	the	the	DET
ajlm-1282	2	9	management	management	NOUN
ajlm-1282	2	10	of	of	ADP
ajlm-1282	2	11	severe	severe	ADJ
ajlm-1282	2	12	covid-19	covid-19	PROPN
ajlm-1282	2	13	cases	case	NOUN
ajlm-1282	2	14	in	in	ADP
ajlm-1282	2	15	limited	limited	ADJ
ajlm-1282	2	16	resource	resource	NOUN
ajlm-1282	2	17	contexts	contexts	NOUN
ajlm-1282	2	18	?	?	PUNCT
ajlm-1282	3	1	afr	afr	PROPN
ajlm-1282	3	2	j	j	PROPN
ajlm-1282	3	3	lab	lab	PROPN
ajlm-1282	3	4	med	me	VERB
ajlm-1282	3	5	.	.	PUNCT
ajlm-1282	3	6	2020;9(1	2020;9(1	NUM
ajlm-1282	3	7	)	)	PUNCT
ajlm-1282	3	8	,	,	PUNCT
ajlm-1282	3	9	a1282	a1282	PROPN
ajlm-1282	3	10	.	.	PUNCT
ajlm-1282	4	1	https://doi.org/10.4102/ajlm.v9i1.1282	https://doi.org/10.4102/ajlm.v9i1.1282	PROPN
ajlm-1282	4	2	opinion	opinion	NOUN
ajlm-1282	4	3	paper	paper	NOUN
ajlm-1282	4	4	how	how	SCONJ
ajlm-1282	4	5	can	can	AUX
ajlm-1282	4	6	clinical	clinical	VERB
ajlm-1282	4	7	immunology	immunology	NOUN
ajlm-1282	4	8	laboratories	laboratory	NOUN
ajlm-1282	4	9	contribute	contribute	VERB
ajlm-1282	4	10	to	to	ADP
ajlm-1282	4	11	the	the	DET
ajlm-1282	4	12	management	management	NOUN
ajlm-1282	4	13	of	of	ADP
ajlm-1282	4	14	severe	severe	ADJ
ajlm-1282	4	15	covid-19	covid-19	PROPN
ajlm-1282	4	16	cases	case	NOUN
ajlm-1282	4	17	in	in	ADP
ajlm-1282	4	18	limited	limited	ADJ
ajlm-1282	4	19	resource	resource	NOUN
ajlm-1282	4	20	contexts	contexts	NOUN
ajlm-1282	4	21	?	?	PUNCT
ajlm-1282	5	1	brahim	brahim	PROPN
ajlm-1282	5	2	admou	admou	ADV
ajlm-1282	5	3	,	,	PUNCT
ajlm-1282	5	4	abdelhamid	abdelhamid	PROPN
ajlm-1282	5	5	hachimi	hachimi	PROPN
ajlm-1282	5	6	,	,	PUNCT
ajlm-1282	5	7	mohamed	mohamed	PROPN
ajlm-1282	5	8	abdenasser	abdenasser	PROPN
ajlm-1282	6	1	samkaoui	samkaoui	PROPN
ajlm-1282	6	2	received	receive	VERB
ajlm-1282	6	3	:	:	PUNCT
ajlm-1282	6	4	27	27	NUM
ajlm-1282	6	5	may	may	PROPN
ajlm-1282	6	6	2020	2020	NUM
ajlm-1282	6	7	;	;	PUNCT
ajlm-1282	6	8	accepted	accept	VERB
ajlm-1282	6	9	:	:	PUNCT
ajlm-1282	6	10	03	03	NUM
ajlm-1282	6	11	sept	sept	PROPN
ajlm-1282	6	12	.	.	PROPN
ajlm-1282	6	13	2020	2020	NUM
ajlm-1282	6	14	;	;	PUNCT
ajlm-1282	6	15	published	publish	VERB
ajlm-1282	6	16	:	:	PUNCT
ajlm-1282	6	17	02	02	NUM
ajlm-1282	6	18	nov	nov	PROPN
ajlm-1282	6	19	.	.	PROPN
ajlm-1282	6	20	2020	2020	NUM
ajlm-1282	6	21	copyright	copyright	NOUN
ajlm-1282	6	22	:	:	PUNCT
ajlm-1282	6	23	©	©	PROPN
ajlm-1282	6	24	2020	2020	NUM
ajlm-1282	6	25	.	.	PUNCT
ajlm-1282	7	1	the	the	DET
ajlm-1282	7	2	author(s	author(s	PROPN
ajlm-1282	7	3	)	)	PUNCT
ajlm-1282	7	4	.	.	PUNCT
ajlm-1282	8	1	licensee	licensee	NOUN
ajlm-1282	8	2	:	:	PUNCT
ajlm-1282	8	3	aosis	aosis	NOUN
ajlm-1282	8	4	.	.	PUNCT
ajlm-1282	9	1	this	this	PRON
ajlm-1282	9	2	is	be	AUX
ajlm-1282	9	3	an	an	DET
ajlm-1282	9	4	open	open	ADJ
ajlm-1282	9	5	access	access	NOUN
ajlm-1282	9	6	article	article	NOUN
ajlm-1282	9	7	distributed	distribute	VERB
ajlm-1282	9	8	under	under	ADP
ajlm-1282	9	9	the	the	DET
ajlm-1282	9	10	terms	term	NOUN
ajlm-1282	9	11	of	of	ADP
ajlm-1282	9	12	the	the	DET
ajlm-1282	9	13	creative	creative	ADJ
ajlm-1282	9	14	commons	common	NOUN
ajlm-1282	9	15	attribution	attribution	NOUN
ajlm-1282	9	16	license	license	NOUN
ajlm-1282	9	17	,	,	PUNCT
ajlm-1282	9	18	which	which	PRON
ajlm-1282	9	19	permits	permit	VERB
ajlm-1282	9	20	unrestricted	unrestricted	ADJ
ajlm-1282	9	21	use	use	NOUN
ajlm-1282	9	22	,	,	PUNCT
ajlm-1282	9	23	distribution	distribution	NOUN
ajlm-1282	9	24	,	,	PUNCT
ajlm-1282	9	25	and	and	CCONJ
ajlm-1282	9	26	reproduction	reproduction	NOUN
ajlm-1282	9	27	in	in	ADP
ajlm-1282	9	28	any	any	DET
ajlm-1282	9	29	medium	medium	NOUN
ajlm-1282	9	30	,	,	PUNCT
ajlm-1282	9	31	provided	provide	VERB
ajlm-1282	9	32	the	the	DET
ajlm-1282	9	33	original	original	ADJ
ajlm-1282	9	34	work	work	NOUN
ajlm-1282	9	35	is	be	AUX
ajlm-1282	9	36	properly	properly	ADV
ajlm-1282	9	37	cited	cite	VERB
ajlm-1282	9	38	.	.	PUNCT
ajlm-1282	10	1	introduction	introduction	NOUN
ajlm-1282	10	2	since	since	SCONJ
ajlm-1282	10	3	its	its	PRON
ajlm-1282	10	4	appearance	appearance	NOUN
ajlm-1282	10	5	,	,	PUNCT
ajlm-1282	10	6	the	the	DET
ajlm-1282	10	7	coronavirus	coronavirus	NOUN
ajlm-1282	10	8	disease	disease	NOUN
ajlm-1282	10	9	2019	2019	NUM
ajlm-1282	10	10	(	(	PUNCT
ajlm-1282	10	11	covid-19	covid-19	PROPN
ajlm-1282	10	12	)	)	PUNCT
ajlm-1282	10	13	that	that	PRON
ajlm-1282	10	14	is	be	AUX
ajlm-1282	10	15	caused	cause	VERB
ajlm-1282	10	16	by	by	ADP
ajlm-1282	10	17	severe	severe	ADJ
ajlm-1282	10	18	acute	acute	ADJ
ajlm-1282	10	19	respiratory	respiratory	ADJ
ajlm-1282	10	20	disease	disease	NOUN
ajlm-1282	10	21	coronavirus	coronavirus	NOUN
ajlm-1282	10	22	2	2	NUM
ajlm-1282	10	23	(	(	PUNCT
ajlm-1282	10	24	sars	sar	NOUN
ajlm-1282	10	25	-	-	PUNCT
ajlm-1282	10	26	cov-2	cov-2	NOUN
ajlm-1282	10	27	)	)	PUNCT
ajlm-1282	10	28	,	,	PUNCT
ajlm-1282	10	29	has	have	AUX
ajlm-1282	10	30	been	be	AUX
ajlm-1282	10	31	responsible	responsible	ADJ
ajlm-1282	10	32	for	for	ADP
ajlm-1282	10	33	severe	severe	ADJ
ajlm-1282	10	34	respiratory	respiratory	ADJ
ajlm-1282	10	35	disease	disease	NOUN
ajlm-1282	10	36	similar	similar	ADJ
ajlm-1282	10	37	to	to	ADP
ajlm-1282	10	38	diseases	disease	NOUN
ajlm-1282	10	39	commonly	commonly	ADV
ajlm-1282	10	40	associated	associate	VERB
ajlm-1282	10	41	with	with	ADP
ajlm-1282	10	42	the	the	DET
ajlm-1282	10	43	coronaviruses	coronaviruse	NOUN
ajlm-1282	10	44	such	such	ADJ
ajlm-1282	10	45	as	as	ADP
ajlm-1282	10	46	severe	severe	ADJ
ajlm-1282	10	47	acute	acute	ADJ
ajlm-1282	10	48	respiratory	respiratory	ADJ
ajlm-1282	10	49	syndrome	syndrome	NOUN
ajlm-1282	10	50	and	and	CCONJ
ajlm-1282	10	51	middle	middle	PROPN
ajlm-1282	10	52	east	east	PROPN
ajlm-1282	10	53	respiratory	respiratory	ADJ
ajlm-1282	10	54	syndrome	syndrome	NOUN
ajlm-1282	10	55	;	;	PUNCT
ajlm-1282	10	56	covid-19	covid-19	PROPN
ajlm-1282	10	57	frequently	frequently	ADV
ajlm-1282	10	58	requires	require	VERB
ajlm-1282	10	59	hospitalisation	hospitalisation	NOUN
ajlm-1282	10	60	in	in	ADP
ajlm-1282	10	61	the	the	DET
ajlm-1282	10	62	intensive	intensive	ADJ
ajlm-1282	10	63	care	care	NOUN
ajlm-1282	10	64	unit	unit	NOUN
ajlm-1282	10	65	and	and	CCONJ
ajlm-1282	10	66	has	have	AUX
ajlm-1282	10	67	had	have	VERB
ajlm-1282	10	68	a	a	DET
ajlm-1282	10	69	high	high	ADJ
ajlm-1282	10	70	mortality	mortality	NOUN
ajlm-1282	10	71	rate.1	rate.1	VERB
ajlm-1282	10	72	the	the	DET
ajlm-1282	10	73	severity	severity	NOUN
ajlm-1282	10	74	of	of	ADP
ajlm-1282	10	75	covid-19	covid-19	PROPN
ajlm-1282	10	76	is	be	AUX
ajlm-1282	10	77	generally	generally	ADV
ajlm-1282	10	78	stratified	stratify	VERB
ajlm-1282	10	79	as	as	ADP
ajlm-1282	10	80	asymptomatic	asymptomatic	ADJ
ajlm-1282	10	81	,	,	PUNCT
ajlm-1282	10	82	mild	mild	ADJ
ajlm-1282	10	83	(	(	PUNCT
ajlm-1282	10	84	without	without	ADP
ajlm-1282	10	85	signs	sign	NOUN
ajlm-1282	10	86	of	of	ADP
ajlm-1282	10	87	severe	severe	ADJ
ajlm-1282	10	88	or	or	CCONJ
ajlm-1282	10	89	critical	critical	ADJ
ajlm-1282	10	90	illness	illness	NOUN
ajlm-1282	10	91	)	)	PUNCT
ajlm-1282	10	92	,	,	PUNCT
ajlm-1282	10	93	severe	severe	ADJ
ajlm-1282	10	94	(	(	PUNCT
ajlm-1282	10	95	with	with	ADP
ajlm-1282	10	96	signs	sign	NOUN
ajlm-1282	10	97	of	of	ADP
ajlm-1282	10	98	breathing	breathe	VERB
ajlm-1282	10	99	difficulties	difficulty	NOUN
ajlm-1282	10	100	)	)	PUNCT
ajlm-1282	10	101	or	or	CCONJ
ajlm-1282	10	102	critical	critical	ADJ
ajlm-1282	10	103	(	(	PUNCT
ajlm-1282	10	104	with	with	ADP
ajlm-1282	10	105	signs	sign	NOUN
ajlm-1282	10	106	of	of	ADP
ajlm-1282	10	107	respiratory	respiratory	ADJ
ajlm-1282	10	108	failure	failure	NOUN
ajlm-1282	10	109	,	,	PUNCT
ajlm-1282	10	110	shock	shock	NOUN
ajlm-1282	10	111	and	and	CCONJ
ajlm-1282	10	112	multiple	multiple	ADJ
ajlm-1282	10	113	organ	organ	NOUN
ajlm-1282	10	114	failure).2	failure).2	ADV
ajlm-1282	10	115	the	the	DET
ajlm-1282	10	116	contribution	contribution	NOUN
ajlm-1282	10	117	of	of	ADP
ajlm-1282	10	118	the	the	DET
ajlm-1282	10	119	medical	medical	ADJ
ajlm-1282	10	120	laboratory	laboratory	NOUN
ajlm-1282	10	121	to	to	ADP
ajlm-1282	10	122	the	the	DET
ajlm-1282	10	123	categorisation	categorisation	NOUN
ajlm-1282	10	124	of	of	ADP
ajlm-1282	10	125	covid-19	covid-19	PROPN
ajlm-1282	10	126	clinical	clinical	ADJ
ajlm-1282	10	127	forms	form	NOUN
ajlm-1282	10	128	is	be	AUX
ajlm-1282	10	129	not	not	PART
ajlm-1282	10	130	yet	yet	ADV
ajlm-1282	10	131	well	well	ADV
ajlm-1282	10	132	defined.3	defined.3	NOUN
ajlm-1282	10	133	after	after	ADP
ajlm-1282	10	134	confirmation	confirmation	NOUN
ajlm-1282	10	135	of	of	ADP
ajlm-1282	10	136	infection	infection	NOUN
ajlm-1282	10	137	by	by	ADP
ajlm-1282	10	138	real	real	ADJ
ajlm-1282	10	139	-	-	PUNCT
ajlm-1282	10	140	time	time	NOUN
ajlm-1282	10	141	polymerase	polymerase	NOUN
ajlm-1282	10	142	chain	chain	NOUN
ajlm-1282	10	143	reaction	reaction	NOUN
ajlm-1282	10	144	,	,	PUNCT
ajlm-1282	10	145	biochemical	biochemical	ADJ
ajlm-1282	10	146	and	and	CCONJ
ajlm-1282	10	147	haematological	haematological	ADJ
ajlm-1282	10	148	analyses	analysis	NOUN
ajlm-1282	10	149	provide	provide	VERB
ajlm-1282	10	150	fundamental	fundamental	ADJ
ajlm-1282	10	151	biological	biological	ADJ
ajlm-1282	10	152	parameters	parameter	NOUN
ajlm-1282	10	153	for	for	ADP
ajlm-1282	10	154	determining	determine	VERB
ajlm-1282	10	155	disease	disease	NOUN
ajlm-1282	10	156	severity	severity	NOUN
ajlm-1282	10	157	.	.	PUNCT
ajlm-1282	11	1	similarly	similarly	ADV
ajlm-1282	11	2	,	,	PUNCT
ajlm-1282	11	3	the	the	DET
ajlm-1282	11	4	clinical	clinical	ADJ
ajlm-1282	11	5	immunology	immunology	NOUN
ajlm-1282	11	6	laboratory	laboratory	NOUN
ajlm-1282	11	7	could	could	AUX
ajlm-1282	11	8	play	play	VERB
ajlm-1282	11	9	an	an	DET
ajlm-1282	11	10	important	important	ADJ
ajlm-1282	11	11	role	role	NOUN
ajlm-1282	11	12	in	in	ADP
ajlm-1282	11	13	elucidating	elucidate	VERB
ajlm-1282	11	14	diverse	diverse	ADJ
ajlm-1282	11	15	immunological	immunological	ADJ
ajlm-1282	11	16	abnormalities	abnormality	NOUN
ajlm-1282	11	17	associated	associate	VERB
ajlm-1282	11	18	with	with	ADP
ajlm-1282	11	19	the	the	DET
ajlm-1282	11	20	disease	disease	NOUN
ajlm-1282	11	21	.	.	PUNCT
ajlm-1282	12	1	in	in	ADP
ajlm-1282	12	2	particular	particular	ADJ
ajlm-1282	12	3	,	,	PUNCT
ajlm-1282	12	4	immunological	immunological	ADJ
ajlm-1282	12	5	testing	testing	NOUN
ajlm-1282	12	6	could	could	AUX
ajlm-1282	12	7	better	well	ADV
ajlm-1282	12	8	categorise	categorise	VERB
ajlm-1282	12	9	the	the	DET
ajlm-1282	12	10	severe	severe	ADJ
ajlm-1282	12	11	and	and	CCONJ
ajlm-1282	12	12	critical	critical	ADJ
ajlm-1282	12	13	forms	form	NOUN
ajlm-1282	12	14	of	of	ADP
ajlm-1282	12	15	covid-19	covid-19	PROPN
ajlm-1282	12	16	,	,	PUNCT
ajlm-1282	12	17	and	and	CCONJ
ajlm-1282	12	18	subsequently	subsequently	ADV
ajlm-1282	12	19	assist	assist	VERB
ajlm-1282	12	20	treating	treat	VERB
ajlm-1282	12	21	physicians	physician	NOUN
ajlm-1282	12	22	during	during	ADP
ajlm-1282	12	23	the	the	DET
ajlm-1282	12	24	entire	entire	ADJ
ajlm-1282	12	25	course	course	NOUN
ajlm-1282	12	26	of	of	ADP
ajlm-1282	12	27	therapy	therapy	NOUN
ajlm-1282	12	28	.	.	PUNCT
ajlm-1282	13	1	the	the	DET
ajlm-1282	13	2	purpose	purpose	NOUN
ajlm-1282	13	3	of	of	ADP
ajlm-1282	13	4	this	this	DET
ajlm-1282	13	5	opinion	opinion	NOUN
ajlm-1282	13	6	article	article	NOUN
ajlm-1282	13	7	is	be	AUX
ajlm-1282	13	8	to	to	PART
ajlm-1282	13	9	highlight	highlight	VERB
ajlm-1282	13	10	the	the	DET
ajlm-1282	13	11	position	position	NOUN
ajlm-1282	13	12	of	of	ADP
ajlm-1282	13	13	the	the	DET
ajlm-1282	13	14	immunology	immunology	NOUN
ajlm-1282	13	15	laboratory	laboratory	NOUN
ajlm-1282	13	16	in	in	ADP
ajlm-1282	13	17	the	the	DET
ajlm-1282	13	18	management	management	NOUN
ajlm-1282	13	19	of	of	ADP
ajlm-1282	13	20	severe	severe	ADJ
ajlm-1282	13	21	and	and	CCONJ
ajlm-1282	13	22	critical	critical	ADJ
ajlm-1282	13	23	covid-19	covid-19	PROPN
ajlm-1282	13	24	cases	case	NOUN
ajlm-1282	13	25	,	,	PUNCT
ajlm-1282	13	26	specifically	specifically	ADV
ajlm-1282	13	27	in	in	ADP
ajlm-1282	13	28	countries	country	NOUN
ajlm-1282	13	29	with	with	ADP
ajlm-1282	13	30	limited	limited	ADJ
ajlm-1282	13	31	resources	resource	NOUN
ajlm-1282	13	32	.	.	PUNCT
ajlm-1282	14	1	covid-19	covid-19	PROPN
ajlm-1282	14	2	and	and	CCONJ
ajlm-1282	14	3	cytokine	cytokine	VERB
ajlm-1282	14	4	storm	storm	NOUN
ajlm-1282	14	5	covid-19	covid-19	PROPN
ajlm-1282	14	6	is	be	AUX
ajlm-1282	14	7	marked	mark	VERB
ajlm-1282	14	8	by	by	ADP
ajlm-1282	14	9	an	an	DET
ajlm-1282	14	10	overproduction	overproduction	NOUN
ajlm-1282	14	11	of	of	ADP
ajlm-1282	14	12	pro	pro	ADJ
ajlm-1282	14	13	-	-	ADJ
ajlm-1282	14	14	inflammatory	inflammatory	ADJ
ajlm-1282	14	15	cytokines	cytokine	NOUN
ajlm-1282	14	16	and	and	CCONJ
ajlm-1282	14	17	chemokines	chemokine	NOUN
ajlm-1282	14	18	,	,	PUNCT
ajlm-1282	14	19	mainly	mainly	ADV
ajlm-1282	14	20	interleukin	interleukin	NOUN
ajlm-1282	14	21	(	(	PUNCT
ajlm-1282	14	22	il)-6	il)-6	NUM
ajlm-1282	14	23	,	,	PUNCT
ajlm-1282	14	24	il-10	il-10	PRON
ajlm-1282	14	25	,	,	PUNCT
ajlm-1282	14	26	tumor	tumor	NOUN
ajlm-1282	14	27	necrosis	necrosis	NOUN
ajlm-1282	14	28	factor	factor	NOUN
ajlm-1282	14	29	(	(	PUNCT
ajlm-1282	14	30	tnf)-α	tnf)-α	PROPN
ajlm-1282	14	31	,	,	PUNCT
ajlm-1282	14	32	il-1β	il-1β	PROPN
ajlm-1282	14	33	,	,	PUNCT
ajlm-1282	14	34	il-2	il-2	PROPN
ajlm-1282	14	35	,	,	PUNCT
ajlm-1282	14	36	il-10	il-10	PRON
ajlm-1282	14	37	,	,	PUNCT
ajlm-1282	14	38	interferon	interferon	ADJ
ajlm-1282	14	39	-	-	PUNCT
ajlm-1282	14	40	γ	γ	NOUN
ajlm-1282	14	41	and	and	CCONJ
ajlm-1282	14	42	monocyte	monocyte	PROPN
ajlm-1282	14	43	chemoattractant	chemoattractant	NOUN
ajlm-1282	14	44	protein-1.4	protein-1.4	VERB
ajlm-1282	14	45	other	other	ADJ
ajlm-1282	14	46	biological	biological	ADJ
ajlm-1282	14	47	abnormalities	abnormality	NOUN
ajlm-1282	14	48	may	may	AUX
ajlm-1282	14	49	predict	predict	VERB
ajlm-1282	14	50	the	the	DET
ajlm-1282	14	51	severity	severity	NOUN
ajlm-1282	14	52	or	or	CCONJ
ajlm-1282	14	53	progression	progression	NOUN
ajlm-1282	14	54	of	of	ADP
ajlm-1282	14	55	the	the	DET
ajlm-1282	14	56	disease	disease	NOUN
ajlm-1282	14	57	,	,	PUNCT
ajlm-1282	14	58	such	such	ADJ
ajlm-1282	14	59	as	as	ADP
ajlm-1282	14	60	abnormal	abnormal	ADJ
ajlm-1282	14	61	coagulation	coagulation	NOUN
ajlm-1282	14	62	activation	activation	NOUN
ajlm-1282	14	63	,	,	PUNCT
ajlm-1282	14	64	leukopenia	leukopenia	PROPN
ajlm-1282	14	65	,	,	PUNCT
ajlm-1282	14	66	high	high	ADJ
ajlm-1282	14	67	levels	level	NOUN
ajlm-1282	14	68	of	of	ADP
ajlm-1282	14	69	c	c	NOUN
ajlm-1282	14	70	-	-	PUNCT
ajlm-1282	14	71	reactive	reactive	ADJ
ajlm-1282	14	72	protein	protein	NOUN
ajlm-1282	14	73	,	,	PUNCT
ajlm-1282	14	74	ferritin	ferritin	ADJ
ajlm-1282	14	75	,	,	PUNCT
ajlm-1282	14	76	d	d	NOUN
ajlm-1282	14	77	-	-	PUNCT
ajlm-1282	14	78	dimers	dimer	NOUN
ajlm-1282	14	79	,	,	PUNCT
ajlm-1282	14	80	aminotransferase	aminotransferase	NOUN
ajlm-1282	14	81	,	,	PUNCT
ajlm-1282	14	82	lactate	lactate	NOUN
ajlm-1282	14	83	dehydrogenase	dehydrogenase	NOUN
ajlm-1282	14	84	and	and	CCONJ
ajlm-1282	14	85	creatin	creatin	VERB
ajlm-1282	14	86	kinase.3,5	kinase.3,5	NUM
ajlm-1282	14	87	elevated	elevated	ADJ
ajlm-1282	14	88	levels	level	NOUN
ajlm-1282	14	89	of	of	ADP
ajlm-1282	14	90	pro	pro	ADJ
ajlm-1282	14	91	-	-	ADJ
ajlm-1282	14	92	inflammatory	inflammatory	ADJ
ajlm-1282	14	93	cytokines	cytokine	NOUN
ajlm-1282	14	94	have	have	AUX
ajlm-1282	14	95	been	be	AUX
ajlm-1282	14	96	shown	show	VERB
ajlm-1282	14	97	to	to	PART
ajlm-1282	14	98	characterise	characterise	VERB
ajlm-1282	14	99	severe	severe	ADJ
ajlm-1282	14	100	lung	lung	NOUN
ajlm-1282	14	101	infection	infection	NOUN
ajlm-1282	14	102	,	,	PUNCT
ajlm-1282	14	103	which	which	PRON
ajlm-1282	14	104	manifests	manifest	VERB
ajlm-1282	14	105	as	as	ADP
ajlm-1282	14	106	respiratory	respiratory	ADJ
ajlm-1282	14	107	distress	distress	NOUN
ajlm-1282	14	108	,	,	PUNCT
ajlm-1282	14	109	multiple	multiple	ADJ
ajlm-1282	14	110	organ	organ	NOUN
ajlm-1282	14	111	failure	failure	NOUN
ajlm-1282	14	112	and	and	CCONJ
ajlm-1282	14	113	adverse	adverse	ADJ
ajlm-1282	14	114	outcomes	outcome	NOUN
ajlm-1282	14	115	in	in	ADP
ajlm-1282	14	116	sars	sar	NOUN
ajlm-1282	14	117	-	-	PUNCT
ajlm-1282	14	118	cov-2	cov-2	NOUN
ajlm-1282	14	119	infection.6,7	infection.6,7	NOUN
ajlm-1282	14	120	in	in	ADP
ajlm-1282	14	121	addition	addition	NOUN
ajlm-1282	14	122	,	,	PUNCT
ajlm-1282	14	123	il-6	il-6	NUM
ajlm-1282	14	124	,	,	PUNCT
ajlm-1282	14	125	il-10	il-10	PRON
ajlm-1282	14	126	,	,	PUNCT
ajlm-1282	14	127	and	and	CCONJ
ajlm-1282	14	128	tnf	tnf	PROPN
ajlm-1282	14	129	-	-	PUNCT
ajlm-1282	14	130	α	α	PROPN
ajlm-1282	14	131	levels	level	NOUN
ajlm-1282	14	132	significantly	significantly	ADV
ajlm-1282	14	133	increase	increase	VERB
ajlm-1282	14	134	during	during	ADP
ajlm-1282	14	135	infection	infection	NOUN
ajlm-1282	14	136	and	and	CCONJ
ajlm-1282	14	137	drop	drop	VERB
ajlm-1282	14	138	during	during	ADP
ajlm-1282	14	139	recovery,8	recovery,8	NOUN
ajlm-1282	14	140	suggesting	suggest	VERB
ajlm-1282	14	141	that	that	SCONJ
ajlm-1282	14	142	the	the	DET
ajlm-1282	14	143	intensity	intensity	NOUN
ajlm-1282	14	144	of	of	ADP
ajlm-1282	14	145	the	the	DET
ajlm-1282	14	146	cytokine	cytokine	NOUN
ajlm-1282	14	147	release	release	NOUN
ajlm-1282	14	148	correlates	correlate	VERB
ajlm-1282	14	149	with	with	ADP
ajlm-1282	14	150	disease	disease	NOUN
ajlm-1282	14	151	activity	activity	NOUN
ajlm-1282	14	152	.	.	PUNCT
ajlm-1282	15	1	interestingly	interestingly	ADV
ajlm-1282	15	2	,	,	PUNCT
ajlm-1282	15	3	il-6	il-6	PRON
ajlm-1282	15	4	may	may	AUX
ajlm-1282	15	5	be	be	AUX
ajlm-1282	15	6	a	a	DET
ajlm-1282	15	7	marker	marker	NOUN
ajlm-1282	15	8	for	for	ADP
ajlm-1282	15	9	monitoring	monitor	VERB
ajlm-1282	15	10	serious	serious	ADJ
ajlm-1282	15	11	covid-19	covid-19	PROPN
ajlm-1282	15	12	cases.9	cases.9	PROPN
ajlm-1282	15	13	moreover	moreover	ADV
ajlm-1282	15	14	,	,	PUNCT
ajlm-1282	15	15	simultaneous	simultaneous	ADJ
ajlm-1282	15	16	high	high	ADJ
ajlm-1282	15	17	levels	level	NOUN
ajlm-1282	15	18	of	of	ADP
ajlm-1282	15	19	il-6	il-6	NUM
ajlm-1282	15	20	and	and	CCONJ
ajlm-1282	15	21	d	d	NOUN
ajlm-1282	15	22	-	-	PUNCT
ajlm-1282	15	23	dimers	dimer	NOUN
ajlm-1282	15	24	have	have	AUX
ajlm-1282	15	25	been	be	AUX
ajlm-1282	15	26	shown	show	VERB
ajlm-1282	15	27	to	to	PART
ajlm-1282	15	28	be	be	AUX
ajlm-1282	15	29	narrowly	narrowly	ADV
ajlm-1282	15	30	associated	associate	VERB
ajlm-1282	15	31	with	with	ADP
ajlm-1282	15	32	severe	severe	ADJ
ajlm-1282	15	33	forms	form	NOUN
ajlm-1282	15	34	of	of	ADP
ajlm-1282	15	35	the	the	DET
ajlm-1282	15	36	disease	disease	NOUN
ajlm-1282	15	37	in	in	ADP
ajlm-1282	15	38	adult	adult	NOUN
ajlm-1282	15	39	patients	patient	NOUN
ajlm-1282	15	40	.	.	PUNCT
ajlm-1282	16	1	therefore	therefore	ADV
ajlm-1282	16	2	,	,	PUNCT
ajlm-1282	16	3	measuring	measure	VERB
ajlm-1282	16	4	them	they	PRON
ajlm-1282	16	5	in	in	ADP
ajlm-1282	16	6	combination	combination	NOUN
ajlm-1282	16	7	allows	allow	VERB
ajlm-1282	16	8	for	for	ADP
ajlm-1282	16	9	greater	great	ADJ
ajlm-1282	16	10	specificity	specificity	NOUN
ajlm-1282	16	11	and	and	CCONJ
ajlm-1282	16	12	sensitivity	sensitivity	NOUN
ajlm-1282	16	13	for	for	ADP
ajlm-1282	16	14	predicting	predict	VERB
ajlm-1282	16	15	severe	severe	ADJ
ajlm-1282	16	16	cases	case	NOUN
ajlm-1282	16	17	of	of	ADP
ajlm-1282	16	18	covid-19.3	covid-19.3	PROPN
ajlm-1282	16	19	covid-19	covid-19	PROPN
ajlm-1282	16	20	and	and	CCONJ
ajlm-1282	16	21	t	t	NOUN
ajlm-1282	16	22	cell	cell	NOUN
ajlm-1282	16	23	impairment	impairment	ADJ
ajlm-1282	16	24	deregulation	deregulation	NOUN
ajlm-1282	16	25	of	of	ADP
ajlm-1282	16	26	the	the	DET
ajlm-1282	16	27	immune	immune	ADJ
ajlm-1282	16	28	response	response	NOUN
ajlm-1282	16	29	,	,	PUNCT
ajlm-1282	16	30	particularly	particularly	ADV
ajlm-1282	16	31	t	t	PROPN
ajlm-1282	16	32	lymphocytes	lymphocyte	NOUN
ajlm-1282	16	33	,	,	PUNCT
ajlm-1282	16	34	appears	appear	VERB
ajlm-1282	16	35	to	to	PART
ajlm-1282	16	36	be	be	AUX
ajlm-1282	16	37	strongly	strongly	ADV
ajlm-1282	16	38	linked	link	VERB
ajlm-1282	16	39	to	to	ADP
ajlm-1282	16	40	the	the	DET
ajlm-1282	16	41	pathology	pathology	NOUN
ajlm-1282	16	42	of	of	ADP
ajlm-1282	16	43	covid-1910	covid-1910	NOUN
ajlm-1282	16	44	;	;	PUNCT
ajlm-1282	16	45	direct	direct	ADJ
ajlm-1282	16	46	infection	infection	NOUN
ajlm-1282	16	47	of	of	ADP
ajlm-1282	16	48	lymphocytes	lymphocyte	NOUN
ajlm-1282	16	49	by	by	ADP
ajlm-1282	16	50	sars	sar	NOUN
ajlm-1282	16	51	-	-	PUNCT
ajlm-1282	16	52	cov-2	cov-2	PART
ajlm-1282	16	53	has	have	AUX
ajlm-1282	16	54	been	be	AUX
ajlm-1282	16	55	proposed	propose	VERB
ajlm-1282	16	56	as	as	ADP
ajlm-1282	16	57	a	a	DET
ajlm-1282	16	58	cause	cause	NOUN
ajlm-1282	16	59	for	for	ADP
ajlm-1282	16	60	acute	acute	ADJ
ajlm-1282	16	61	lymphocyte	lymphocyte	ADJ
ajlm-1282	16	62	decline.3,11	decline.3,11	PROPN
ajlm-1282	16	63	lymphocytes	lymphocyte	NOUN
ajlm-1282	16	64	express	express	VERB
ajlm-1282	16	65	the	the	DET
ajlm-1282	16	66	receptor	receptor	NOUN
ajlm-1282	16	67	angiotensin	angiotensin	NOUN
ajlm-1282	16	68	-	-	PUNCT
ajlm-1282	16	69	converting	convert	VERB
ajlm-1282	16	70	enzyme	enzyme	NOUN
ajlm-1282	16	71	2	2	NUM
ajlm-1282	16	72	,	,	PUNCT
ajlm-1282	16	73	which	which	PRON
ajlm-1282	16	74	has	have	AUX
ajlm-1282	16	75	been	be	AUX
ajlm-1282	16	76	suggested	suggest	VERB
ajlm-1282	16	77	to	to	PART
ajlm-1282	16	78	be	be	AUX
ajlm-1282	16	79	the	the	DET
ajlm-1282	16	80	primary	primary	ADJ
ajlm-1282	16	81	receptor	receptor	NOUN
ajlm-1282	16	82	targeted	target	VERB
ajlm-1282	16	83	by	by	ADP
ajlm-1282	16	84	sars	sar	NOUN
ajlm-1282	16	85	-	-	PUNCT
ajlm-1282	16	86	cov-2.12	cov-2.12	NOUN
ajlm-1282	16	87	moreover	moreover	ADV
ajlm-1282	16	88	,	,	PUNCT
ajlm-1282	16	89	altered	alter	VERB
ajlm-1282	16	90	t	t	PROPN
ajlm-1282	16	91	lymphocytes	lymphocyte	NOUN
ajlm-1282	16	92	could	could	AUX
ajlm-1282	16	93	be	be	AUX
ajlm-1282	16	94	an	an	DET
ajlm-1282	16	95	important	important	ADJ
ajlm-1282	16	96	factor	factor	NOUN
ajlm-1282	16	97	in	in	ADP
ajlm-1282	16	98	worsening	worsen	VERB
ajlm-1282	16	99	symptoms	symptom	NOUN
ajlm-1282	16	100	in	in	ADP
ajlm-1282	16	101	patients	patient	NOUN
ajlm-1282	16	102	,	,	PUNCT
ajlm-1282	16	103	which	which	PRON
ajlm-1282	16	104	makes	make	VERB
ajlm-1282	16	105	lymphopenia	lymphopenia	NOUN
ajlm-1282	16	106	a	a	DET
ajlm-1282	16	107	relevant	relevant	ADJ
ajlm-1282	16	108	marker	marker	NOUN
ajlm-1282	16	109	of	of	ADP
ajlm-1282	16	110	disease	disease	NOUN
ajlm-1282	16	111	severity	severity	NOUN
ajlm-1282	16	112	,	,	PUNCT
ajlm-1282	16	113	hence	hence	ADV
ajlm-1282	16	114	the	the	DET
ajlm-1282	16	115	need	need	NOUN
ajlm-1282	16	116	for	for	ADP
ajlm-1282	16	117	intensive	intensive	ADJ
ajlm-1282	16	118	care	care	NOUN
ajlm-1282	16	119	unit	unit	NOUN
ajlm-1282	16	120	admission.11	admission.11	NOUN
ajlm-1282	16	121	it	it	PRON
ajlm-1282	16	122	has	have	AUX
ajlm-1282	16	123	been	be	AUX
ajlm-1282	16	124	demonstrated	demonstrate	VERB
ajlm-1282	16	125	that	that	SCONJ
ajlm-1282	16	126	the	the	DET
ajlm-1282	16	127	severe	severe	ADJ
ajlm-1282	16	128	respiratory	respiratory	ADJ
ajlm-1282	16	129	syndrome	syndrome	NOUN
ajlm-1282	16	130	that	that	PRON
ajlm-1282	16	131	manifests	manifest	VERB
ajlm-1282	16	132	due	due	ADJ
ajlm-1282	16	133	to	to	ADP
ajlm-1282	16	134	covid-19	covid-19	PROPN
ajlm-1282	16	135	is	be	AUX
ajlm-1282	16	136	characterised	characterise	VERB
ajlm-1282	16	137	by	by	ADP
ajlm-1282	16	138	cluster	cluster	NOUN
ajlm-1282	16	139	of	of	ADP
ajlm-1282	16	140	differentiation	differentiation	NOUN
ajlm-1282	16	141	(	(	PUNCT
ajlm-1282	16	142	cd)4	cd)4	PROPN
ajlm-1282	16	143	and	and	CCONJ
ajlm-1282	16	144	cd8	cd8	PROPN
ajlm-1282	16	145	t	t	PROPN
ajlm-1282	16	146	lymphopenia	lymphopenia	NOUN
ajlm-1282	16	147	,	,	PUNCT
ajlm-1282	16	148	correlating	correlate	VERB
ajlm-1282	16	149	with	with	ADP
ajlm-1282	16	150	disease	disease	NOUN
ajlm-1282	16	151	severity.4,13	severity.4,13	VERB
ajlm-1282	16	152	on	on	ADP
ajlm-1282	16	153	the	the	DET
ajlm-1282	16	154	other	other	ADJ
ajlm-1282	16	155	hand	hand	NOUN
ajlm-1282	16	156	,	,	PUNCT
ajlm-1282	16	157	covid-19	covid-19	PROPN
ajlm-1282	16	158	patients	patient	NOUN
ajlm-1282	16	159	who	who	PRON
ajlm-1282	16	160	require	require	VERB
ajlm-1282	16	161	intensive	intensive	ADJ
ajlm-1282	16	162	care	care	NOUN
ajlm-1282	16	163	unit	unit	NOUN
ajlm-1282	16	164	hospitalisation	hospitalisation	NOUN
ajlm-1282	16	165	have	have	VERB
ajlm-1282	16	166	significantly	significantly	ADV
ajlm-1282	16	167	higher	high	ADJ
ajlm-1282	16	168	levels	level	NOUN
ajlm-1282	16	169	of	of	ADP
ajlm-1282	16	170	il-6	il-6	NOUN
ajlm-1282	16	171	,	,	PUNCT
ajlm-1282	16	172	il-10	il-10	PRON
ajlm-1282	16	173	and	and	CCONJ
ajlm-1282	16	174	tnf	tnf	PROPN
ajlm-1282	16	175	-	-	PUNCT
ajlm-1282	16	176	α	α	PROPN
ajlm-1282	16	177	,	,	PUNCT
ajlm-1282	16	178	with	with	ADP
ajlm-1282	16	179	lower	low	ADJ
ajlm-1282	16	180	levels	level	NOUN
ajlm-1282	16	181	of	of	ADP
ajlm-1282	16	182	cd4	cd4	PROPN
ajlm-1282	16	183	and	and	CCONJ
ajlm-1282	16	184	cd8	cd8	PROPN
ajlm-1282	16	185	t	t	PROPN
ajlm-1282	16	186	cell	cell	NOUN
ajlm-1282	16	187	counts,8	counts,8	PUNCT
ajlm-1282	16	188	with	with	ADP
ajlm-1282	16	189	which	which	DET
ajlm-1282	16	190	levels	level	NOUN
ajlm-1282	16	191	of	of	ADP
ajlm-1282	16	192	cytokines	cytokine	NOUN
ajlm-1282	16	193	and	and	CCONJ
ajlm-1282	16	194	t	t	NOUN
ajlm-1282	16	195	cells	cell	NOUN
ajlm-1282	16	196	are	be	AUX
ajlm-1282	16	197	inversely	inversely	ADV
ajlm-1282	16	198	correlated.6,8	correlated.6,8	ADJ
ajlm-1282	16	199	moreover	moreover	ADV
ajlm-1282	16	200	,	,	PUNCT
ajlm-1282	16	201	because	because	SCONJ
ajlm-1282	16	202	t	t	PROPN
ajlm-1282	16	203	lymphocytes	lymphocyte	NOUN
ajlm-1282	16	204	are	be	AUX
ajlm-1282	16	205	generally	generally	ADV
ajlm-1282	16	206	crucial	crucial	ADJ
ajlm-1282	16	207	for	for	ADP
ajlm-1282	16	208	amortising	amortise	VERB
ajlm-1282	16	209	exaggerated	exaggerated	ADJ
ajlm-1282	16	210	natural	natural	ADJ
ajlm-1282	16	211	immune	immune	ADJ
ajlm-1282	16	212	reactions	reaction	NOUN
ajlm-1282	16	213	against	against	ADP
ajlm-1282	16	214	viral	viral	ADJ
ajlm-1282	16	215	infection	infection	NOUN
ajlm-1282	16	216	,	,	PUNCT
ajlm-1282	16	217	t	t	NOUN
ajlm-1282	16	218	cell	cell	NOUN
ajlm-1282	16	219	defects	defect	NOUN
ajlm-1282	16	220	can	can	AUX
ajlm-1282	16	221	lead	lead	VERB
ajlm-1282	16	222	to	to	ADP
ajlm-1282	16	223	worsening	worsen	VERB
ajlm-1282	16	224	inflammatory	inflammatory	ADJ
ajlm-1282	16	225	responses	response	NOUN
ajlm-1282	16	226	during	during	ADP
ajlm-1282	16	227	covid-19	covid-19	PROPN
ajlm-1282	16	228	,	,	PUNCT
ajlm-1282	16	229	whereas	whereas	SCONJ
ajlm-1282	16	230	restoring	restore	VERB
ajlm-1282	16	231	the	the	DET
ajlm-1282	16	232	number	number	NOUN
ajlm-1282	16	233	of	of	ADP
ajlm-1282	16	234	these	these	DET
ajlm-1282	16	235	lymphocytes	lymphocyte	NOUN
ajlm-1282	16	236	can	can	AUX
ajlm-1282	16	237	improve	improve	VERB
ajlm-1282	16	238	them.6	them.6	PROPN
ajlm-1282	16	239	in	in	ADP
ajlm-1282	16	240	accordance	accordance	NOUN
ajlm-1282	16	241	with	with	ADP
ajlm-1282	16	242	this	this	DET
ajlm-1282	16	243	hypothesis	hypothesis	NOUN
ajlm-1282	16	244	,	,	PUNCT
ajlm-1282	16	245	it	it	PRON
ajlm-1282	16	246	has	have	AUX
ajlm-1282	16	247	been	be	AUX
ajlm-1282	16	248	shown	show	VERB
ajlm-1282	16	249	that	that	SCONJ
ajlm-1282	16	250	4–6	4–6	NUM
ajlm-1282	16	251	days	day	NOUN
ajlm-1282	16	252	following	follow	VERB
ajlm-1282	16	253	the	the	DET
ajlm-1282	16	254	onset	onset	NOUN
ajlm-1282	16	255	of	of	ADP
ajlm-1282	16	256	infection	infection	NOUN
ajlm-1282	16	257	,	,	PUNCT
ajlm-1282	16	258	t	t	PROPN
ajlm-1282	16	259	lymphocyte	lymphocyte	NOUN
ajlm-1282	16	260	counts	count	NOUN
ajlm-1282	16	261	drop	drop	VERB
ajlm-1282	16	262	to	to	ADP
ajlm-1282	16	263	their	their	PRON
ajlm-1282	16	264	lowest	low	ADJ
ajlm-1282	16	265	level	level	NOUN
ajlm-1282	16	266	,	,	PUNCT
ajlm-1282	16	267	whereas	whereas	SCONJ
ajlm-1282	16	268	cytokine	cytokine	ADJ
ajlm-1282	16	269	levels	level	NOUN
ajlm-1282	16	270	reach	reach	VERB
ajlm-1282	16	271	their	their	PRON
ajlm-1282	16	272	maximum	maximum	NOUN
ajlm-1282	16	273	.	.	PUNCT
ajlm-1282	17	1	conversely	conversely	ADV
ajlm-1282	17	2	,	,	PUNCT
ajlm-1282	17	3	the	the	DET
ajlm-1282	17	4	restoration	restoration	NOUN
ajlm-1282	17	5	of	of	ADP
ajlm-1282	17	6	the	the	DET
ajlm-1282	17	7	number	number	NOUN
ajlm-1282	17	8	of	of	ADP
ajlm-1282	17	9	t	t	PROPN
ajlm-1282	17	10	lymphocytes	lymphocyte	NOUN
ajlm-1282	17	11	is	be	AUX
ajlm-1282	17	12	associated	associate	VERB
ajlm-1282	17	13	with	with	ADP
ajlm-1282	17	14	a	a	DET
ajlm-1282	17	15	decrease	decrease	NOUN
ajlm-1282	17	16	in	in	ADP
ajlm-1282	17	17	serum	serum	NOUN
ajlm-1282	17	18	levels	level	NOUN
ajlm-1282	17	19	of	of	ADP
ajlm-1282	17	20	various	various	ADJ
ajlm-1282	17	21	cytokines	cytokine	NOUN
ajlm-1282	17	22	,	,	PUNCT
ajlm-1282	17	23	such	such	ADJ
ajlm-1282	17	24	as	as	ADP
ajlm-1282	17	25	il-6	il-6	NUM
ajlm-1282	17	26	,	,	PUNCT
ajlm-1282	17	27	il-10	il-10	PRON
ajlm-1282	17	28	and	and	CCONJ
ajlm-1282	17	29	tnf	tnf	PROPN
ajlm-1282	17	30	-	-	PUNCT
ajlm-1282	17	31	α.6	α.6	NOUN
ajlm-1282	17	32	owing	owe	VERB
ajlm-1282	17	33	to	to	ADP
ajlm-1282	17	34	the	the	DET
ajlm-1282	17	35	cytokine	cytokine	NOUN
ajlm-1282	17	36	storm	storm	NOUN
ajlm-1282	17	37	,	,	PUNCT
ajlm-1282	17	38	and	and	CCONJ
ajlm-1282	17	39	other	other	ADJ
ajlm-1282	17	40	immunological	immunological	ADJ
ajlm-1282	17	41	predictors	predictor	NOUN
ajlm-1282	17	42	of	of	ADP
ajlm-1282	17	43	severity	severity	NOUN
ajlm-1282	17	44	of	of	ADP
ajlm-1282	17	45	sars	sars	PROPN
ajlm-1282	17	46	-	-	PUNCT
ajlm-1282	17	47	cov2	cov2	PROPN
ajlm-1282	17	48	infection	infection	NOUN
ajlm-1282	17	49	,	,	PUNCT
ajlm-1282	17	50	these	these	PRON
ajlm-1282	17	51	may	may	AUX
ajlm-1282	17	52	also	also	ADV
ajlm-1282	17	53	be	be	AUX
ajlm-1282	17	54	helpful	helpful	ADJ
ajlm-1282	17	55	in	in	ADP
ajlm-1282	17	56	choosing	choose	VERB
ajlm-1282	17	57	anti	anti	ADJ
ajlm-1282	17	58	-	-	ADJ
ajlm-1282	17	59	inflammatory	inflammatory	ADJ
ajlm-1282	17	60	drugs	drug	NOUN
ajlm-1282	17	61	,	,	PUNCT
ajlm-1282	17	62	especially	especially	ADV
ajlm-1282	17	63	corticosteroids	corticosteroid	NOUN
ajlm-1282	17	64	for	for	ADP
ajlm-1282	17	65	their	their	PRON
ajlm-1282	17	66	potential	potential	ADJ
ajlm-1282	17	67	benefit	benefit	NOUN
ajlm-1282	17	68	in	in	ADP
ajlm-1282	17	69	the	the	DET
ajlm-1282	17	70	reduction	reduction	NOUN
ajlm-1282	17	71	of	of	ADP
ajlm-1282	17	72	inflammation	inflammation	NOUN
ajlm-1282	17	73	-	-	PUNCT
ajlm-1282	17	74	induced	induce	VERB
ajlm-1282	17	75	lung	lung	NOUN
ajlm-1282	17	76	damage	damage	NOUN
ajlm-1282	17	77	in	in	ADP
ajlm-1282	17	78	severe	severe	ADJ
ajlm-1282	17	79	covid-19	covid-19	PROPN
ajlm-1282	17	80	patients.1	patients.1	NOUN
ajlm-1282	17	81	covid-19	covid-19	PROPN
ajlm-1282	17	82	and	and	CCONJ
ajlm-1282	17	83	immunological	immunological	ADJ
ajlm-1282	17	84	investigations	investigation	NOUN
ajlm-1282	17	85	having	having	AUX
ajlm-1282	17	86	shown	show	VERB
ajlm-1282	17	87	that	that	SCONJ
ajlm-1282	17	88	the	the	DET
ajlm-1282	17	89	most	most	ADV
ajlm-1282	17	90	relevant	relevant	ADJ
ajlm-1282	17	91	immunological	immunological	ADJ
ajlm-1282	17	92	parameters	parameter	NOUN
ajlm-1282	17	93	include	include	VERB
ajlm-1282	17	94	inflammatory	inflammatory	ADJ
ajlm-1282	17	95	cytokines	cytokine	NOUN
ajlm-1282	17	96	and	and	CCONJ
ajlm-1282	17	97	t	t	X
ajlm-1282	17	98	lymphocyte	lymphocyte	ADJ
ajlm-1282	17	99	subpopulations	subpopulation	NOUN
ajlm-1282	17	100	,	,	PUNCT
ajlm-1282	17	101	the	the	DET
ajlm-1282	17	102	clinical	clinical	ADJ
ajlm-1282	17	103	immunology	immunology	NOUN
ajlm-1282	17	104	laboratory	laboratory	NOUN
ajlm-1282	17	105	is	be	AUX
ajlm-1282	17	106	positioned	position	VERB
ajlm-1282	17	107	to	to	PART
ajlm-1282	17	108	be	be	AUX
ajlm-1282	17	109	important	important	ADJ
ajlm-1282	17	110	for	for	ADP
ajlm-1282	17	111	assessing	assess	VERB
ajlm-1282	17	112	covid-19	covid-19	PROPN
ajlm-1282	17	113	patients	patient	NOUN
ajlm-1282	17	114	,	,	PUNCT
ajlm-1282	17	115	especially	especially	ADV
ajlm-1282	17	116	for	for	ADP
ajlm-1282	17	117	categorising	categorise	VERB
ajlm-1282	17	118	,	,	PUNCT
ajlm-1282	17	119	or	or	CCONJ
ajlm-1282	17	120	even	even	ADV
ajlm-1282	17	121	predicting	predict	VERB
ajlm-1282	17	122	severe	severe	ADJ
ajlm-1282	17	123	cases.2,10	cases.2,10	NOUN
ajlm-1282	17	124	cytokine	cytokine	NOUN
ajlm-1282	17	125	levels	level	NOUN
ajlm-1282	17	126	,	,	PUNCT
ajlm-1282	17	127	especially	especially	ADV
ajlm-1282	17	128	that	that	PRON
ajlm-1282	17	129	of	of	ADP
ajlm-1282	17	130	il-6	il-6	NUM
ajlm-1282	17	131	,	,	PUNCT
ajlm-1282	17	132	can	can	AUX
ajlm-1282	17	133	be	be	AUX
ajlm-1282	17	134	individually	individually	ADV
ajlm-1282	17	135	measured	measure	VERB
ajlm-1282	17	136	on	on	ADP
ajlm-1282	17	137	immunoassay	immunoassay	ADJ
ajlm-1282	17	138	analysers	analyser	NOUN
ajlm-1282	17	139	,	,	PUNCT
ajlm-1282	17	140	whereas	whereas	SCONJ
ajlm-1282	17	141	other	other	ADJ
ajlm-1282	17	142	cytokine	cytokine	NOUN
ajlm-1282	17	143	profiles	profile	NOUN
ajlm-1282	17	144	can	can	AUX
ajlm-1282	17	145	be	be	AUX
ajlm-1282	17	146	explored	explore	VERB
ajlm-1282	17	147	using	use	VERB
ajlm-1282	17	148	either	either	CCONJ
ajlm-1282	17	149	enzyme	enzyme	NOUN
ajlm-1282	17	150	-	-	PUNCT
ajlm-1282	17	151	linked	link	VERB
ajlm-1282	17	152	immunosorbent	immunosorbent	ADJ
ajlm-1282	17	153	assays	assay	NOUN
ajlm-1282	17	154	or	or	CCONJ
ajlm-1282	17	155	other	other	ADJ
ajlm-1282	17	156	specific	specific	ADJ
ajlm-1282	17	157	biotechnologies	biotechnology	NOUN
ajlm-1282	17	158	like	like	ADP
ajlm-1282	17	159	luminex	luminex	PROPN
ajlm-1282	17	160	®	®	NOUN
ajlm-1282	17	161	,	,	PUNCT
ajlm-1282	17	162	200	200	NUM
ajlm-1282	17	163	™	™	NOUN
ajlm-1282	17	164	(	(	PUNCT
ajlm-1282	17	165	or	or	CCONJ
ajlm-1282	17	166	multiplex	multiplex	PROPN
ajlm-1282	17	167	)	)	PUNCT
ajlm-1282	17	168	(	(	PUNCT
ajlm-1282	17	169	luminex	luminex	PROPN
ajlm-1282	17	170	®	®	PROPN
ajlm-1282	17	171	,	,	PUNCT
ajlm-1282	17	172	austin	austin	PROPN
ajlm-1282	17	173	,	,	PUNCT
ajlm-1282	17	174	texas	texas	PROPN
ajlm-1282	17	175	,	,	PUNCT
ajlm-1282	17	176	united	united	PROPN
ajlm-1282	17	177	states	states	PROPN
ajlm-1282	17	178	)	)	PUNCT
ajlm-1282	17	179	and	and	CCONJ
ajlm-1282	17	180	flow	flow	VERB
ajlm-1282	17	181	cytometry	cytometry	NOUN
ajlm-1282	17	182	systems	system	NOUN
ajlm-1282	17	183	,	,	PUNCT
ajlm-1282	17	184	which	which	PRON
ajlm-1282	17	185	allow	allow	VERB
ajlm-1282	17	186	for	for	ADP
ajlm-1282	17	187	a	a	DET
ajlm-1282	17	188	large	large	ADJ
ajlm-1282	17	189	-	-	PUNCT
ajlm-1282	17	190	scale	scale	NOUN
ajlm-1282	17	191	quantitative	quantitative	ADJ
ajlm-1282	17	192	measurement.14	measurement.14	NOUN
ajlm-1282	17	193	the	the	DET
ajlm-1282	17	194	assessment	assessment	NOUN
ajlm-1282	17	195	of	of	ADP
ajlm-1282	17	196	the	the	DET
ajlm-1282	17	197	main	main	ADJ
ajlm-1282	17	198	t	t	NOUN
ajlm-1282	17	199	cell	cell	NOUN
ajlm-1282	17	200	subsets	subset	NOUN
ajlm-1282	17	201	,	,	PUNCT
ajlm-1282	17	202	such	such	ADJ
ajlm-1282	17	203	as	as	ADP
ajlm-1282	17	204	cd3	cd3	PROPN
ajlm-1282	17	205	+	+	PROPN
ajlm-1282	17	206	,	,	PUNCT
ajlm-1282	17	207	cd4	cd4	PROPN
ajlm-1282	17	208	+	+	PROPN
ajlm-1282	17	209	and	and	CCONJ
ajlm-1282	17	210	cd8	cd8	PROPN
ajlm-1282	17	211	+	+	PROPN
ajlm-1282	17	212	,	,	PUNCT
ajlm-1282	17	213	requires	require	VERB
ajlm-1282	17	214	only	only	ADV
ajlm-1282	17	215	a	a	DET
ajlm-1282	17	216	simple	simple	ADJ
ajlm-1282	17	217	phenotyping	phenotype	VERB
ajlm-1282	17	218	procedure	procedure	NOUN
ajlm-1282	17	219	conductible	conductible	NOUN
ajlm-1282	17	220	on	on	ADP
ajlm-1282	17	221	a	a	DET
ajlm-1282	17	222	mini	mini	NOUN
ajlm-1282	17	223	-	-	NOUN
ajlm-1282	17	224	cytometer	cytometer	NOUN
ajlm-1282	17	225	,	,	PUNCT
ajlm-1282	17	226	which	which	PRON
ajlm-1282	17	227	is	be	AUX
ajlm-1282	17	228	largely	largely	ADV
ajlm-1282	17	229	available	available	ADJ
ajlm-1282	17	230	worldwide	worldwide	ADV
ajlm-1282	17	231	even	even	ADV
ajlm-1282	17	232	in	in	ADP
ajlm-1282	17	233	limited	limited	ADJ
ajlm-1282	17	234	-	-	PUNCT
ajlm-1282	17	235	resource	resource	NOUN
ajlm-1282	17	236	context	context	NOUN
ajlm-1282	17	237	laboratories	laboratory	NOUN
ajlm-1282	17	238	,	,	PUNCT
ajlm-1282	17	239	thanks	thank	NOUN
ajlm-1282	17	240	to	to	ADP
ajlm-1282	17	241	hiv	hiv	PROPN
ajlm-1282	17	242	management	management	NOUN
ajlm-1282	17	243	programs	program	NOUN
ajlm-1282	17	244	.	.	PUNCT
ajlm-1282	18	1	more	more	ADV
ajlm-1282	18	2	developed	develop	VERB
ajlm-1282	18	3	flow	flow	NOUN
ajlm-1282	18	4	cytometry	cytometry	NOUN
ajlm-1282	18	5	platforms	platform	NOUN
ajlm-1282	18	6	allow	allow	VERB
ajlm-1282	18	7	for	for	ADP
ajlm-1282	18	8	comprehensive	comprehensive	ADJ
ajlm-1282	18	9	phenotyping	phenotype	VERB
ajlm-1282	18	10	assays	assay	NOUN
ajlm-1282	18	11	,	,	PUNCT
ajlm-1282	18	12	enabling	enable	VERB
ajlm-1282	18	13	the	the	DET
ajlm-1282	18	14	investigation	investigation	NOUN
ajlm-1282	18	15	of	of	ADP
ajlm-1282	18	16	naive	naive	ADJ
ajlm-1282	18	17	,	,	PUNCT
ajlm-1282	18	18	memory	memory	NOUN
ajlm-1282	18	19	and	and	CCONJ
ajlm-1282	18	20	regulatory	regulatory	ADJ
ajlm-1282	18	21	t	t	NOUN
ajlm-1282	18	22	cells	cell	NOUN
ajlm-1282	18	23	;	;	PUNCT
ajlm-1282	18	24	in	in	ADP
ajlm-1282	18	25	severe	severe	ADJ
ajlm-1282	18	26	covid-19	covid-19	PROPN
ajlm-1282	18	27	patients	patient	NOUN
ajlm-1282	18	28	,	,	PUNCT
ajlm-1282	18	29	early	early	ADJ
ajlm-1282	18	30	data	datum	NOUN
ajlm-1282	18	31	on	on	ADP
ajlm-1282	18	32	t	t	PROPN
ajlm-1282	18	33	cell	cell	NOUN
ajlm-1282	18	34	subpopulation	subpopulation	NOUN
ajlm-1282	18	35	abnormalities	abnormality	NOUN
ajlm-1282	18	36	show	show	VERB
ajlm-1282	18	37	increased	increase	VERB
ajlm-1282	18	38	naive	naive	ADJ
ajlm-1282	18	39	helper	helper	NOUN
ajlm-1282	18	40	t	t	NOUN
ajlm-1282	18	41	cells	cell	NOUN
ajlm-1282	18	42	and	and	CCONJ
ajlm-1282	18	43	decreased	decrease	VERB
ajlm-1282	18	44	memory	memory	NOUN
ajlm-1282	18	45	helper	helper	NOUN
ajlm-1282	18	46	t	t	PROPN
ajlm-1282	18	47	cells	cell	NOUN
ajlm-1282	18	48	,	,	PUNCT
ajlm-1282	18	49	associated	associate	VERB
ajlm-1282	18	50	with	with	ADP
ajlm-1282	18	51	a	a	DET
ajlm-1282	18	52	lower	low	ADJ
ajlm-1282	18	53	number	number	NOUN
ajlm-1282	18	54	of	of	ADP
ajlm-1282	18	55	regulatory	regulatory	ADJ
ajlm-1282	18	56	t	t	PROPN
ajlm-1282	18	57	cells.10	cells.10	NOUN
ajlm-1282	18	58	using	use	VERB
ajlm-1282	18	59	a	a	DET
ajlm-1282	18	60	receiver	receiver	ADJ
ajlm-1282	18	61	operating	operate	VERB
ajlm-1282	18	62	characteristic	characteristic	ADJ
ajlm-1282	18	63	curve	curve	NOUN
ajlm-1282	18	64	to	to	PART
ajlm-1282	18	65	compare	compare	VERB
ajlm-1282	18	66	fatal	fatal	ADJ
ajlm-1282	18	67	and	and	CCONJ
ajlm-1282	18	68	recovered	recover	VERB
ajlm-1282	18	69	covid-19	covid-19	PROPN
ajlm-1282	18	70	cases	case	NOUN
ajlm-1282	18	71	,	,	PUNCT
ajlm-1282	18	72	xu	xu	PROPN
ajlm-1282	18	73	et	et	PROPN
ajlm-1282	19	1	al.2	al.2	PROPN
ajlm-1282	19	2	considered	consider	VERB
ajlm-1282	19	3	559	559	NUM
ajlm-1282	19	4	cells/µl	cells/µl	NOUN
ajlm-1282	19	5	,	,	PUNCT
ajlm-1282	19	6	235	235	NUM
ajlm-1282	19	7	cells/µl	cells/µl	NOUN
ajlm-1282	19	8	,	,	PUNCT
ajlm-1282	19	9	and	and	CCONJ
ajlm-1282	19	10	104	104	NUM
ajlm-1282	19	11	cells/µl	cells/µl	NOUN
ajlm-1282	19	12	of	of	ADP
ajlm-1282	19	13	cd3	cd3	PROPN
ajlm-1282	19	14	+	+	PROPN
ajlm-1282	19	15	,	,	PUNCT
ajlm-1282	19	16	cd4+t	cd4+t	ADJ
ajlm-1282	19	17	,	,	PUNCT
ajlm-1282	19	18	and	and	CCONJ
ajlm-1282	19	19	cd8	cd8	PROPN
ajlm-1282	19	20	+	+	PROPN
ajlm-1282	19	21	t	t	NOUN
ajlm-1282	19	22	cell	cell	NOUN
ajlm-1282	19	23	subsets	subset	NOUN
ajlm-1282	19	24	as	as	ADP
ajlm-1282	19	25	warning	warning	NOUN
ajlm-1282	19	26	values	value	NOUN
ajlm-1282	19	27	,	,	PUNCT
ajlm-1282	19	28	below	below	ADP
ajlm-1282	19	29	which	which	PRON
ajlm-1282	19	30	there	there	PRON
ajlm-1282	19	31	was	be	VERB
ajlm-1282	19	32	a	a	DET
ajlm-1282	19	33	significantly	significantly	ADV
ajlm-1282	19	34	higher	high	ADJ
ajlm-1282	19	35	risk	risk	NOUN
ajlm-1282	19	36	of	of	ADP
ajlm-1282	19	37	in	in	ADP
ajlm-1282	19	38	-	-	PUNCT
ajlm-1282	19	39	hospital	hospital	NOUN
ajlm-1282	19	40	death.2	death.2	NOUN
ajlm-1282	19	41	indeed	indeed	ADV
ajlm-1282	19	42	,	,	PUNCT
ajlm-1282	19	43	there	there	PRON
ajlm-1282	19	44	is	be	VERB
ajlm-1282	19	45	a	a	DET
ajlm-1282	19	46	need	need	NOUN
ajlm-1282	19	47	for	for	ADP
ajlm-1282	19	48	regional	regional	ADJ
ajlm-1282	19	49	data	datum	NOUN
ajlm-1282	19	50	analyses	analysis	NOUN
ajlm-1282	19	51	before	before	ADP
ajlm-1282	19	52	determining	determine	VERB
ajlm-1282	19	53	cut	cut	VERB
ajlm-1282	19	54	-	-	PUNCT
ajlm-1282	19	55	off	off	ADP
ajlm-1282	19	56	values	value	NOUN
ajlm-1282	19	57	of	of	ADP
ajlm-1282	19	58	these	these	DET
ajlm-1282	19	59	t	t	NOUN
ajlm-1282	19	60	cell	cell	NOUN
ajlm-1282	19	61	subsets	subset	NOUN
ajlm-1282	19	62	.	.	PUNCT
ajlm-1282	20	1	however	however	ADV
ajlm-1282	20	2	,	,	PUNCT
ajlm-1282	20	3	t	t	PROPN
ajlm-1282	20	4	cell	cell	NOUN
ajlm-1282	20	5	lymphopenia	lymphopenia	NOUN
ajlm-1282	20	6	might	might	AUX
ajlm-1282	20	7	be	be	AUX
ajlm-1282	20	8	accentuated	accentuate	VERB
ajlm-1282	20	9	by	by	ADP
ajlm-1282	20	10	possible	possible	ADJ
ajlm-1282	20	11	primary	primary	ADJ
ajlm-1282	20	12	or	or	CCONJ
ajlm-1282	20	13	acquired	acquire	VERB
ajlm-1282	20	14	immune	immune	ADJ
ajlm-1282	20	15	deficiency	deficiency	NOUN
ajlm-1282	20	16	conditions	condition	NOUN
ajlm-1282	20	17	,	,	PUNCT
ajlm-1282	20	18	potentially	potentially	ADV
ajlm-1282	20	19	revealed	reveal	VERB
ajlm-1282	20	20	by	by	ADP
ajlm-1282	20	21	covid-19	covid-19	PROPN
ajlm-1282	20	22	,	,	PUNCT
ajlm-1282	20	23	and	and	CCONJ
ajlm-1282	20	24	must	must	AUX
ajlm-1282	20	25	then	then	ADV
ajlm-1282	20	26	be	be	AUX
ajlm-1282	20	27	considered	consider	VERB
ajlm-1282	20	28	first	first	ADV
ajlm-1282	20	29	when	when	SCONJ
ajlm-1282	20	30	interpreting	interpret	VERB
ajlm-1282	20	31	cell	cell	NOUN
ajlm-1282	20	32	phenotyping	phenotype	VERB
ajlm-1282	20	33	values	value	NOUN
ajlm-1282	20	34	and	and	CCONJ
ajlm-1282	20	35	when	when	SCONJ
ajlm-1282	20	36	managing	manage	VERB
ajlm-1282	20	37	patients	patient	NOUN
ajlm-1282	20	38	as	as	ADP
ajlm-1282	20	39	well.15	well.15	NOUN
ajlm-1282	20	40	conclusion	conclusion	NOUN
ajlm-1282	20	41	for	for	ADP
ajlm-1282	20	42	sars	sar	NOUN
ajlm-1282	20	43	-	-	PUNCT
ajlm-1282	20	44	cov-2	cov-2	PART
ajlm-1282	20	45	infection	infection	NOUN
ajlm-1282	20	46	,	,	PUNCT
ajlm-1282	20	47	alongside	alongside	ADP
ajlm-1282	20	48	other	other	ADJ
ajlm-1282	20	49	clinical	clinical	ADJ
ajlm-1282	20	50	and	and	CCONJ
ajlm-1282	20	51	biological	biological	ADJ
ajlm-1282	20	52	parameters	parameter	NOUN
ajlm-1282	20	53	,	,	PUNCT
ajlm-1282	20	54	the	the	DET
ajlm-1282	20	55	measurement	measurement	NOUN
ajlm-1282	20	56	of	of	ADP
ajlm-1282	20	57	inflammatory	inflammatory	ADJ
ajlm-1282	20	58	cytokines	cytokine	NOUN
ajlm-1282	20	59	,	,	PUNCT
ajlm-1282	20	60	mainly	mainly	ADV
ajlm-1282	20	61	il-6	il-6	NUM
ajlm-1282	20	62	,	,	PUNCT
ajlm-1282	20	63	as	as	ADV
ajlm-1282	20	64	well	well	ADV
ajlm-1282	20	65	as	as	ADP
ajlm-1282	20	66	cd4	cd4	PROPN
ajlm-1282	20	67	+	+	PROPN
ajlm-1282	20	68	and	and	CCONJ
ajlm-1282	20	69	cd8	cd8	PROPN
ajlm-1282	20	70	+	+	PROPN
ajlm-1282	20	71	t	t	PROPN
ajlm-1282	20	72	cell	cell	NOUN
ajlm-1282	20	73	assessment	assessment	NOUN
ajlm-1282	20	74	,	,	PUNCT
ajlm-1282	20	75	should	should	AUX
ajlm-1282	20	76	be	be	AUX
ajlm-1282	20	77	systematically	systematically	ADV
ajlm-1282	20	78	planned	plan	VERB
ajlm-1282	20	79	during	during	ADP
ajlm-1282	20	80	management	management	NOUN
ajlm-1282	20	81	of	of	ADP
ajlm-1282	20	82	the	the	DET
ajlm-1282	20	83	disease	disease	NOUN
ajlm-1282	20	84	.	.	PUNCT
ajlm-1282	21	1	these	these	DET
ajlm-1282	21	2	markers	marker	NOUN
ajlm-1282	21	3	could	could	AUX
ajlm-1282	21	4	be	be	AUX
ajlm-1282	21	5	useful	useful	ADJ
ajlm-1282	21	6	for	for	ADP
ajlm-1282	21	7	identifying	identify	VERB
ajlm-1282	21	8	severe	severe	ADJ
ajlm-1282	21	9	cases	case	NOUN
ajlm-1282	21	10	requiring	require	VERB
ajlm-1282	21	11	prompt	prompt	ADJ
ajlm-1282	21	12	admission	admission	NOUN
ajlm-1282	21	13	to	to	ADP
ajlm-1282	21	14	intensive	intensive	ADJ
ajlm-1282	21	15	care	care	NOUN
ajlm-1282	21	16	units	unit	NOUN
ajlm-1282	21	17	,	,	PUNCT
ajlm-1282	21	18	and	and	CCONJ
ajlm-1282	21	19	for	for	ADP
ajlm-1282	21	20	monitoring	monitor	VERB
ajlm-1282	21	21	patient	patient	ADJ
ajlm-1282	21	22	disease	disease	NOUN
ajlm-1282	21	23	progression	progression	NOUN
ajlm-1282	21	24	.	.	PUNCT
ajlm-1282	22	1	these	these	DET
ajlm-1282	22	2	investigations	investigation	NOUN
ajlm-1282	22	3	are	be	AUX
ajlm-1282	22	4	within	within	ADP
ajlm-1282	22	5	the	the	DET
ajlm-1282	22	6	reach	reach	NOUN
ajlm-1282	22	7	of	of	ADP
ajlm-1282	22	8	almost	almost	ADV
ajlm-1282	22	9	all	all	PRON
ajlm-1282	22	10	clinical	clinical	ADJ
ajlm-1282	22	11	immunology	immunology	NOUN
ajlm-1282	22	12	laboratories	laboratory	NOUN
ajlm-1282	22	13	in	in	ADP
ajlm-1282	22	14	the	the	DET
ajlm-1282	22	15	world	world	NOUN
ajlm-1282	22	16	.	.	PUNCT
ajlm-1282	23	1	close	close	ADJ
ajlm-1282	23	2	collaboration	collaboration	NOUN
ajlm-1282	23	3	between	between	ADP
ajlm-1282	23	4	immunologists	immunologist	NOUN
ajlm-1282	23	5	and	and	CCONJ
ajlm-1282	23	6	physicians	physician	NOUN
ajlm-1282	23	7	is	be	AUX
ajlm-1282	23	8	essential	essential	ADJ
ajlm-1282	23	9	for	for	ADP
ajlm-1282	23	10	effective	effective	ADJ
ajlm-1282	23	11	global	global	ADJ
ajlm-1282	23	12	efforts	effort	NOUN
ajlm-1282	23	13	against	against	ADP
ajlm-1282	23	14	this	this	DET
ajlm-1282	23	15	highly	highly	ADV
ajlm-1282	23	16	threatening	threatening	ADJ
ajlm-1282	23	17	pandemic	pandemic	ADJ
ajlm-1282	23	18	.	.	PUNCT
ajlm-1282	24	1	acknowledgements	acknowledgement	NOUN
ajlm-1282	24	2	we	we	PRON
ajlm-1282	24	3	would	would	AUX
ajlm-1282	24	4	like	like	VERB
ajlm-1282	24	5	to	to	PART
ajlm-1282	24	6	express	express	VERB
ajlm-1282	24	7	our	our	PRON
ajlm-1282	24	8	sincere	sincere	ADJ
ajlm-1282	24	9	gratitude	gratitude	NOUN
ajlm-1282	24	10	and	and	CCONJ
ajlm-1282	24	11	deepest	deepest	VERB
ajlm-1282	24	12	appreciation	appreciation	NOUN
ajlm-1282	24	13	to	to	ADP
ajlm-1282	24	14	yacine	yacine	PROPN
ajlm-1282	24	15	berka	berka	PROPN
ajlm-1282	24	16	for	for	ADP
ajlm-1282	24	17	his	his	PRON
ajlm-1282	24	18	highly	highly	ADV
ajlm-1282	24	19	valuable	valuable	ADJ
ajlm-1282	24	20	contribution	contribution	NOUN
ajlm-1282	24	21	in	in	ADP
ajlm-1282	24	22	the	the	DET
ajlm-1282	24	23	editing	editing	NOUN
ajlm-1282	24	24	of	of	ADP
ajlm-1282	24	25	this	this	DET
ajlm-1282	24	26	manuscript	manuscript	NOUN
ajlm-1282	24	27	.	.	PUNCT
ajlm-1282	25	1	competing	compete	VERB
ajlm-1282	25	2	interests	interest	NOUN
ajlm-1282	25	3	the	the	DET
ajlm-1282	25	4	authors	author	NOUN
ajlm-1282	25	5	have	have	AUX
ajlm-1282	25	6	declared	declare	VERB
ajlm-1282	25	7	that	that	SCONJ
ajlm-1282	25	8	no	no	DET
ajlm-1282	25	9	competing	compete	VERB
ajlm-1282	25	10	interests	interest	NOUN
ajlm-1282	25	11	exist	exist	VERB
ajlm-1282	25	12	.	.	PUNCT
ajlm-1282	26	1	authors	author	NOUN
ajlm-1282	26	2	’	'	PUNCT
ajlm-1282	26	3	contributions	contribution	NOUN
ajlm-1282	26	4	all	all	DET
ajlm-1282	26	5	authors	author	NOUN
ajlm-1282	26	6	contributed	contribute	VERB
ajlm-1282	26	7	equally	equally	ADV
ajlm-1282	26	8	to	to	ADP
ajlm-1282	26	9	this	this	DET
ajlm-1282	26	10	work	work	NOUN
ajlm-1282	26	11	.	.	PUNCT
ajlm-1282	27	1	b.a	b.a	PROPN
ajlm-1282	27	2	.	.	PROPN
ajlm-1282	27	3	conceptualised	conceptualise	VERB
ajlm-1282	27	4	and	and	CCONJ
ajlm-1282	27	5	wrote	write	VERB
ajlm-1282	27	6	the	the	DET
ajlm-1282	27	7	major	major	ADJ
ajlm-1282	27	8	parts	part	NOUN
ajlm-1282	27	9	of	of	ADP
ajlm-1282	27	10	the	the	DET
ajlm-1282	27	11	manuscript	manuscript	NOUN
ajlm-1282	27	12	.	.	PUNCT
ajlm-1282	28	1	a.h	a.h	PROPN
ajlm-1282	28	2	.	.	PROPN
ajlm-1282	28	3	co	co	VERB
ajlm-1282	28	4	-	-	VERB
ajlm-1282	28	5	wrote	write	VERB
ajlm-1282	28	6	the	the	DET
ajlm-1282	28	7	clinical	clinical	ADJ
ajlm-1282	28	8	aspects	aspect	NOUN
ajlm-1282	28	9	of	of	ADP
ajlm-1282	28	10	the	the	DET
ajlm-1282	28	11	manuscript	manuscript	NOUN
ajlm-1282	28	12	.	.	PUNCT
ajlm-1282	29	1	m.a.s	m.a.s	PROPN
ajlm-1282	29	2	.	.	PROPN
ajlm-1282	29	3	contributed	contribute	VERB
ajlm-1282	29	4	to	to	ADP
ajlm-1282	29	5	the	the	DET
ajlm-1282	29	6	conceptualisation	conceptualisation	NOUN
ajlm-1282	29	7	and	and	CCONJ
ajlm-1282	29	8	validated	validate	VERB
ajlm-1282	29	9	a	a	DET
ajlm-1282	29	10	writing	writing	NOUN
ajlm-1282	29	11	review	review	NOUN
ajlm-1282	29	12	of	of	ADP
ajlm-1282	29	13	the	the	DET
ajlm-1282	29	14	manuscript	manuscript	NOUN
ajlm-1282	29	15	.	.	PUNCT
ajlm-1282	30	1	ethical	ethical	ADJ
ajlm-1282	30	2	considerations	consideration	NOUN
ajlm-1282	30	3	ethical	ethical	ADJ
ajlm-1282	30	4	clearance	clearance	NOUN
ajlm-1282	30	5	was	be	AUX
ajlm-1282	30	6	not	not	PART
ajlm-1282	30	7	required	require	VERB
ajlm-1282	30	8	for	for	ADP
ajlm-1282	30	9	this	this	DET
ajlm-1282	30	10	study	study	NOUN
ajlm-1282	30	11	.	.	PUNCT
ajlm-1282	31	1	sources	source	NOUN
ajlm-1282	31	2	of	of	ADP
ajlm-1282	31	3	support	support	NOUN
ajlm-1282	31	4	this	this	DET
ajlm-1282	31	5	research	research	NOUN
ajlm-1282	31	6	received	receive	VERB
ajlm-1282	31	7	no	no	DET
ajlm-1282	31	8	specific	specific	ADJ
ajlm-1282	31	9	grant	grant	NOUN
ajlm-1282	31	10	from	from	ADP
ajlm-1282	31	11	any	any	DET
ajlm-1282	31	12	funding	funding	NOUN
ajlm-1282	31	13	agency	agency	NOUN
ajlm-1282	31	14	in	in	ADP
ajlm-1282	31	15	the	the	DET
ajlm-1282	31	16	public	public	ADJ
ajlm-1282	31	17	commercial	commercial	NOUN
ajlm-1282	31	18	or	or	CCONJ
ajlm-1282	31	19	not	not	PART
ajlm-1282	31	20	-	-	PUNCT
ajlm-1282	31	21	for	for	ADP
ajlm-1282	31	22	-	-	PUNCT
ajlm-1282	31	23	profit	profit	NOUN
ajlm-1282	31	24	sectors	sector	NOUN
ajlm-1282	31	25	.	.	PUNCT
ajlm-1282	32	1	data	datum	NOUN
ajlm-1282	32	2	availability	availability	NOUN
ajlm-1282	32	3	statement	statement	NOUN
ajlm-1282	32	4	data	datum	NOUN
ajlm-1282	32	5	sharing	sharing	NOUN
ajlm-1282	32	6	is	be	AUX
ajlm-1282	32	7	not	not	PART
ajlm-1282	32	8	applicable	applicable	ADJ
ajlm-1282	32	9	to	to	ADP
ajlm-1282	32	10	this	this	DET
ajlm-1282	32	11	article	article	NOUN
ajlm-1282	32	12	as	as	SCONJ
ajlm-1282	32	13	no	no	DET
ajlm-1282	32	14	new	new	ADJ
ajlm-1282	32	15	data	datum	NOUN
ajlm-1282	32	16	were	be	AUX
ajlm-1282	32	17	created	create	VERB
ajlm-1282	32	18	or	or	CCONJ
ajlm-1282	32	19	analysed	analyse	VERB
ajlm-1282	32	20	in	in	ADP
ajlm-1282	32	21	this	this	DET
ajlm-1282	32	22	study	study	NOUN
ajlm-1282	32	23	.	.	PUNCT
ajlm-1282	33	1	disclaimer	disclaimer	VERB
ajlm-1282	33	2	the	the	DET
ajlm-1282	33	3	views	view	NOUN
ajlm-1282	33	4	and	and	CCONJ
ajlm-1282	33	5	opinions	opinion	NOUN
ajlm-1282	33	6	expressed	express	VERB
ajlm-1282	33	7	in	in	ADP
ajlm-1282	33	8	this	this	DET
ajlm-1282	33	9	article	article	NOUN
ajlm-1282	33	10	are	be	AUX
ajlm-1282	33	11	those	those	PRON
ajlm-1282	33	12	of	of	ADP
ajlm-1282	33	13	the	the	DET
ajlm-1282	33	14	authors	author	NOUN
ajlm-1282	33	15	and	and	CCONJ
ajlm-1282	33	16	do	do	AUX
ajlm-1282	33	17	not	not	PART
ajlm-1282	33	18	necessarily	necessarily	ADV
ajlm-1282	33	19	reflect	reflect	VERB
ajlm-1282	33	20	the	the	DET
ajlm-1282	33	21	official	official	ADJ
ajlm-1282	33	22	policy	policy	NOUN
ajlm-1282	33	23	or	or	CCONJ
ajlm-1282	33	24	position	position	NOUN
ajlm-1282	33	25	of	of	ADP
ajlm-1282	33	26	any	any	DET
ajlm-1282	33	27	affiliated	affiliated	ADJ
ajlm-1282	33	28	agency	agency	NOUN
ajlm-1282	33	29	of	of	ADP
ajlm-1282	33	30	the	the	DET
ajlm-1282	33	31	authors	author	NOUN
ajlm-1282	33	32	.	.	PUNCT
ajlm-1282	34	1	references	reference	NOUN
ajlm-1282	34	2	huang	huang	PROPN
ajlm-1282	34	3	c	c	PROPN
ajlm-1282	34	4	,	,	PUNCT
ajlm-1282	34	5	wang	wang	PROPN
ajlm-1282	34	6	y	y	PROPN
ajlm-1282	34	7	,	,	PUNCT
ajlm-1282	34	8	li	li	PROPN
ajlm-1282	34	9	x	x	PROPN
ajlm-1282	34	10	,	,	PUNCT
ajlm-1282	34	11	et	et	PROPN
ajlm-1282	34	12	al	al	PROPN
ajlm-1282	34	13	.	.	PUNCT
ajlm-1282	35	1	clinical	clinical	ADJ
ajlm-1282	35	2	features	feature	NOUN
ajlm-1282	35	3	of	of	ADP
ajlm-1282	35	4	patients	patient	NOUN
ajlm-1282	35	5	infected	infect	VERB
ajlm-1282	35	6	with	with	ADP
ajlm-1282	35	7	2019	2019	NUM
ajlm-1282	35	8	novel	novel	ADJ
ajlm-1282	35	9	coronavirus	coronavirus	NOUN
ajlm-1282	35	10	in	in	ADP
ajlm-1282	35	11	wuhan	wuhan	PROPN
ajlm-1282	35	12	,	,	PUNCT
ajlm-1282	35	13	china	china	PROPN
ajlm-1282	35	14	.	.	PUNCT
ajlm-1282	36	1	lancet	lancet	PROPN
ajlm-1282	36	2	.	.	PUNCT
ajlm-1282	37	1	2020;395(10223):497–506	2020;395(10223):497–506	NOUN
ajlm-1282	37	2	.	.	PUNCT
ajlm-1282	38	1	https://doi.org/10.1016/s0140-6736(20)30183-5	https://doi.org/10.1016/s0140-6736(20)30183-5	PROPN
ajlm-1282	38	2	xu	xu	PROPN
ajlm-1282	38	3	b	b	PROPN
ajlm-1282	38	4	,	,	PUNCT
ajlm-1282	38	5	fan	fan	NOUN
ajlm-1282	38	6	c	c	PROPN
ajlm-1282	38	7	-	-	PUNCT
ajlm-1282	38	8	y	y	PROPN
ajlm-1282	38	9	,	,	PUNCT
ajlm-1282	38	10	wang	wang	PROPN
ajlm-1282	38	11	a	a	PROPN
ajlm-1282	38	12	-	-	PUNCT
ajlm-1282	38	13	l	l	NOUN
ajlm-1282	38	14	,	,	PUNCT
ajlm-1282	38	15	et	et	PROPN
ajlm-1282	38	16	al	al	PROPN
ajlm-1282	38	17	.	.	PROPN
ajlm-1282	38	18	miao	miao	PROPN
ajlm-1282	38	19	.	.	PROPN
ajlm-1282	38	20	suppressed	suppress	VERB
ajlm-1282	38	21	t	t	NOUN
ajlm-1282	38	22	cell	cell	NOUN
ajlm-1282	38	23	-	-	PUNCT
ajlm-1282	38	24	mediated	mediate	VERB
ajlm-1282	38	25	immunity	immunity	NOUN
ajlm-1282	38	26	in	in	ADP
ajlm-1282	38	27	patients	patient	NOUN
ajlm-1282	38	28	with	with	ADP
ajlm-1282	38	29	covid-19	covid-19	PROPN
ajlm-1282	38	30	:	:	PUNCT
ajlm-1282	38	31	a	a	DET
ajlm-1282	38	32	clinical	clinical	ADJ
ajlm-1282	38	33	retrospective	retrospective	ADJ
ajlm-1282	38	34	study	study	NOUN
ajlm-1282	38	35	in	in	ADP
ajlm-1282	38	36	wuhan	wuhan	PROPN
ajlm-1282	38	37	,	,	PUNCT
ajlm-1282	38	38	china	china	PROPN
ajlm-1282	38	39	.	.	PUNCT
ajlm-1282	39	1	j	j	PROPN
ajlm-1282	39	2	infect	infect	PROPN
ajlm-1282	39	3	.	.	PUNCT
ajlm-1282	40	1	81(1):e51	81(1):e51	NUM
ajlm-1282	40	2	–	–	PUNCT
ajlm-1282	40	3	e60	e60	NOUN
ajlm-1282	40	4	.	.	PUNCT
ajlm-1282	41	1	gao	gao	PROPN
ajlm-1282	41	2	y	y	PROPN
ajlm-1282	41	3	,	,	PUNCT
ajlm-1282	41	4	li	li	PROPN
ajlm-1282	41	5	t	t	PROPN
ajlm-1282	41	6	,	,	PUNCT
ajlm-1282	41	7	han	han	PROPN
ajlm-1282	41	8	m	m	PROPN
ajlm-1282	41	9	,	,	PUNCT
ajlm-1282	41	10	et	et	PROPN
ajlm-1282	41	11	al	al	PROPN
ajlm-1282	41	12	.	.	PUNCT
ajlm-1282	42	1	diagnostic	diagnostic	ADJ
ajlm-1282	42	2	utility	utility	NOUN
ajlm-1282	42	3	of	of	ADP
ajlm-1282	42	4	clinical	clinical	ADJ
ajlm-1282	42	5	laboratory	laboratory	NOUN
ajlm-1282	42	6	data	datum	NOUN
ajlm-1282	42	7	determinations	determination	NOUN
ajlm-1282	42	8	for	for	ADP
ajlm-1282	42	9	patients	patient	NOUN
ajlm-1282	42	10	with	with	ADP
ajlm-1282	42	11	the	the	DET
ajlm-1282	42	12	severe	severe	ADJ
ajlm-1282	42	13	covid-19	covid-19	PROPN
ajlm-1282	42	14	.	.	PUNCT
ajlm-1282	43	1	j	j	PROPN
ajlm-1282	43	2	med	med	PROPN
ajlm-1282	43	3	virol	virol	NOUN
ajlm-1282	43	4	.	.	PUNCT
ajlm-1282	44	1	2020;92(7):791–796	2020;92(7):791–796	NUM
ajlm-1282	44	2	.	.	PUNCT
ajlm-1282	45	1	https://doi.org/10.1002/jmv.25770	https://doi.org/10.1002/jmv.25770	VERB
ajlm-1282	45	2	pedersen	pedersen	PROPN
ajlm-1282	45	3	s	s	PROPN
ajlm-1282	45	4	-	-	PUNCT
ajlm-1282	45	5	f	f	PROPN
ajlm-1282	45	6	,	,	PUNCT
ajlm-1282	45	7	ho	ho	PROPN
ajlm-1282	45	8	y	y	PROPN
ajlm-1282	45	9	-	-	PUNCT
ajlm-1282	45	10	c.	c.	PROPN
ajlm-1282	45	11	sars	sars	PROPN
ajlm-1282	45	12	-	-	PUNCT
ajlm-1282	45	13	cov-2	cov-2	NUM
ajlm-1282	45	14	:	:	PUNCT
ajlm-1282	45	15	a	a	DET
ajlm-1282	45	16	storm	storm	NOUN
ajlm-1282	45	17	is	be	AUX
ajlm-1282	45	18	raging	rage	VERB
ajlm-1282	45	19	.	.	PUNCT
ajlm-1282	46	1	j	j	PROPN
ajlm-1282	46	2	clin	clin	PROPN
ajlm-1282	46	3	invest	invest	PROPN
ajlm-1282	46	4	.	.	PUNCT
ajlm-1282	47	1	2020;130(5):2202–2205	2020;130(5):2202–2205	X
ajlm-1282	47	2	.	.	PUNCT
ajlm-1282	47	3	https://doi.org/10.1172/jci137647	https://doi.org/10.1172/jci137647	NOUN
ajlm-1282	47	4	henry	henry	PROPN
ajlm-1282	47	5	b	b	PROPN
ajlm-1282	47	6	-	-	PUNCT
ajlm-1282	47	7	m	m	PROPN
ajlm-1282	47	8	,	,	PUNCT
ajlm-1282	47	9	de	de	PROPN
ajlm-1282	47	10	oliveira	oliveira	PROPN
ajlm-1282	47	11	m	m	PROPN
ajlm-1282	47	12	-	-	PROPN
ajlm-1282	47	13	h	h	PROPN
ajlm-1282	47	14	-	-	PUNCT
ajlm-1282	47	15	s	s	NOUN
ajlm-1282	47	16	,	,	PUNCT
ajlm-1282	47	17	benoit	benoit	NOUN
ajlm-1282	47	18	s	s	PROPN
ajlm-1282	47	19	,	,	PUNCT
ajlm-1282	47	20	et	et	PROPN
ajlm-1282	47	21	al	al	PROPN
ajlm-1282	47	22	.	.	PUNCT
ajlm-1282	47	23	hematologic	hematologic	NOUN
ajlm-1282	47	24	,	,	PUNCT
ajlm-1282	47	25	biochemical	biochemical	ADJ
ajlm-1282	47	26	and	and	CCONJ
ajlm-1282	47	27	immune	immune	ADJ
ajlm-1282	47	28	biomarker	biomarker	NOUN
ajlm-1282	47	29	abnormalities	abnormality	NOUN
ajlm-1282	47	30	associated	associate	VERB
ajlm-1282	47	31	with	with	ADP
ajlm-1282	47	32	severe	severe	ADJ
ajlm-1282	47	33	illness	illness	NOUN
ajlm-1282	47	34	and	and	CCONJ
ajlm-1282	47	35	mortality	mortality	NOUN
ajlm-1282	47	36	in	in	ADP
ajlm-1282	47	37	coronavirus	coronavirus	NOUN
ajlm-1282	47	38	disease	disease	NOUN
ajlm-1282	47	39	2019	2019	NUM
ajlm-1282	47	40	(	(	PUNCT
ajlm-1282	47	41	covid-19	covid-19	PROPN
ajlm-1282	47	42	):	):	PUNCT
ajlm-1282	47	43	a	a	DET
ajlm-1282	47	44	meta	meta	ADJ
ajlm-1282	47	45	-	-	PUNCT
ajlm-1282	47	46	analysis	analysis	NOUN
ajlm-1282	47	47	.	.	PUNCT
ajlm-1282	48	1	clin	clin	PROPN
ajlm-1282	48	2	chem	chem	NOUN
ajlm-1282	48	3	lab	lab	NOUN
ajlm-1282	48	4	med	me	VERB
ajlm-1282	48	5	.	.	PUNCT
ajlm-1282	49	1	2020;58(7):1021–1028	2020;58(7):1021–1028	NUM
ajlm-1282	49	2	.	.	PUNCT
ajlm-1282	50	1	https://doi.org/10.1515/cclm-2020-0369	https://doi.org/10.1515/cclm-2020-0369	VERB
ajlm-1282	50	2	liu	liu	PROPN
ajlm-1282	50	3	j	j	PROPN
ajlm-1282	50	4	,	,	PUNCT
ajlm-1282	50	5	li	li	PROPN
ajlm-1282	50	6	s	s	PROPN
ajlm-1282	50	7	,	,	PUNCT
ajlm-1282	50	8	liu	liu	PROPN
ajlm-1282	50	9	j	j	PROPN
ajlm-1282	50	10	,	,	PUNCT
ajlm-1282	50	11	et	et	PROPN
ajlm-1282	50	12	al	al	PROPN
ajlm-1282	50	13	.	.	PUNCT
ajlm-1282	51	1	longitudinal	longitudinal	ADJ
ajlm-1282	51	2	characteristics	characteristic	NOUN
ajlm-1282	51	3	of	of	ADP
ajlm-1282	51	4	lymphocyte	lymphocyte	ADJ
ajlm-1282	51	5	responses	response	NOUN
ajlm-1282	51	6	and	and	CCONJ
ajlm-1282	51	7	cytokine	cytokine	ADJ
ajlm-1282	51	8	profiles	profile	NOUN
ajlm-1282	51	9	in	in	ADP
ajlm-1282	51	10	the	the	DET
ajlm-1282	51	11	peripheral	peripheral	ADJ
ajlm-1282	51	12	blood	blood	NOUN
ajlm-1282	51	13	of	of	ADP
ajlm-1282	51	14	sars	sar	NOUN
ajlm-1282	51	15	-	-	PUNCT
ajlm-1282	51	16	cov-2	cov-2	NOUN
ajlm-1282	51	17	infected	infected	ADJ
ajlm-1282	51	18	patients	patient	NOUN
ajlm-1282	51	19	.	.	PUNCT
ajlm-1282	52	1	ebio	ebio	PROPN
ajlm-1282	52	2	med	med	PROPN
ajlm-1282	52	3	.	.	PUNCT
ajlm-1282	53	1	2020;55:102763	2020;55:102763	NUM
ajlm-1282	53	2	.	.	PUNCT
ajlm-1282	54	1	https://doi.org/10.1016/j.ebiom.2020.102763	https://doi.org/10.1016/j.ebiom.2020.102763	PROPN
ajlm-1282	54	2	zhou	zhou	PROPN
ajlm-1282	54	3	j	j	PROPN
ajlm-1282	54	4	,	,	PUNCT
ajlm-1282	54	5	chu	chu	PROPN
ajlm-1282	54	6	h.	h.	PROPN
ajlm-1282	54	7	,	,	PUNCT
ajlm-1282	54	8	li	li	PROPN
ajlm-1282	54	9	c	c	PROPN
ajlm-1282	54	10	,	,	PUNCT
ajlm-1282	54	11	et	et	PROPN
ajlm-1282	54	12	al	al	PROPN
ajlm-1282	54	13	.	.	PUNCT
ajlm-1282	55	1	active	active	ADJ
ajlm-1282	55	2	replication	replication	NOUN
ajlm-1282	55	3	of	of	ADP
ajlm-1282	55	4	middle	middle	PROPN
ajlm-1282	55	5	east	east	PROPN
ajlm-1282	55	6	respiratory	respiratory	ADJ
ajlm-1282	55	7	syndrome	syndrome	NOUN
ajlm-1282	55	8	coronavirus	coronavirus	NOUN
ajlm-1282	55	9	and	and	CCONJ
ajlm-1282	55	10	aberrant	aberrant	ADJ
ajlm-1282	55	11	induction	induction	NOUN
ajlm-1282	55	12	of	of	ADP
ajlm-1282	55	13	inflammatory	inflammatory	ADJ
ajlm-1282	55	14	cytokines	cytokine	NOUN
ajlm-1282	55	15	and	and	CCONJ
ajlm-1282	55	16	chemokines	chemokine	NOUN
ajlm-1282	55	17	in	in	ADP
ajlm-1282	55	18	human	human	ADJ
ajlm-1282	55	19	macrophages	macrophage	NOUN
ajlm-1282	55	20	:	:	PUNCT
ajlm-1282	55	21	implications	implication	NOUN
ajlm-1282	55	22	for	for	ADP
ajlm-1282	55	23	pathogenesis	pathogenesis	NOUN
ajlm-1282	55	24	.	.	PUNCT
ajlm-1282	56	1	j	j	PROPN
ajlm-1282	56	2	infect	infect	VERB
ajlm-1282	56	3	dis	dis	PROPN
ajlm-1282	56	4	2014;209(9):1331–1342	2014;209(9):1331–1342	NUM
ajlm-1282	56	5	.	.	PUNCT
ajlm-1282	57	1	https://doi.org/10.1093/infdis/jit504	https://doi.org/10.1093/infdis/jit504	ADV
ajlm-1282	57	2	diao	diao	VERB
ajlm-1282	57	3	b	b	PROPN
ajlm-1282	57	4	,	,	PUNCT
ajlm-1282	57	5	wang	wang	PROPN
ajlm-1282	57	6	c	c	PROPN
ajlm-1282	57	7	,	,	PUNCT
ajlm-1282	57	8	tan	tan	PROPN
ajlm-1282	57	9	y	y	PROPN
ajlm-1282	57	10	,	,	PUNCT
ajlm-1282	57	11	et	et	PROPN
ajlm-1282	57	12	al	al	PROPN
ajlm-1282	57	13	.	.	PUNCT
ajlm-1282	57	14	reduction	reduction	NOUN
ajlm-1282	57	15	and	and	CCONJ
ajlm-1282	57	16	functional	functional	ADJ
ajlm-1282	57	17	exhaustion	exhaustion	NOUN
ajlm-1282	57	18	of	of	ADP
ajlm-1282	57	19	t	t	NOUN
ajlm-1282	57	20	cells	cell	NOUN
ajlm-1282	57	21	in	in	ADP
ajlm-1282	57	22	patients	patient	NOUN
ajlm-1282	57	23	with	with	ADP
ajlm-1282	57	24	coronavirus	coronavirus	NOUN
ajlm-1282	57	25	disease	disease	NOUN
ajlm-1282	57	26	.	.	PUNCT
ajlm-1282	58	1	front	front	ADJ
ajlm-1282	58	2	.	.	PUNCT
ajlm-1282	59	1	immunol	immunol	NOUN
ajlm-1282	59	2	.	.	PUNCT
ajlm-1282	60	1	2020;11:827	2020;11:827	X
ajlm-1282	60	2	.	.	PUNCT
ajlm-1282	61	1	https://doi.org/10.3389/fimmu.2020.00827	https://doi.org/10.3389/fimmu.2020.00827	PROPN
ajlm-1282	61	2	zhu	zhu	PROPN
ajlm-1282	61	3	z	z	PROPN
ajlm-1282	61	4	,	,	PUNCT
ajlm-1282	61	5	cai	cai	PROPN
ajlm-1282	61	6	t	t	PROPN
ajlm-1282	61	7	,	,	PUNCT
ajlm-1282	61	8	fan	fan	PROPN
ajlm-1282	61	9	l	l	PROPN
ajlm-1282	61	10	,	,	PUNCT
ajlm-1282	61	11	et	et	PROPN
ajlm-1282	61	12	al	al	PROPN
ajlm-1282	61	13	.	.	PROPN
ajlm-1282	62	1	clinical	clinical	ADJ
ajlm-1282	62	2	value	value	NOUN
ajlm-1282	62	3	of	of	ADP
ajlm-1282	62	4	immune	immune	NOUN
ajlm-1282	62	5	-	-	PUNCT
ajlm-1282	62	6	inflammatory	inflammatory	ADJ
ajlm-1282	62	7	parameters	parameter	NOUN
ajlm-1282	62	8	to	to	PART
ajlm-1282	62	9	assess	assess	VERB
ajlm-1282	62	10	the	the	DET
ajlm-1282	62	11	severity	severity	NOUN
ajlm-1282	62	12	of	of	ADP
ajlm-1282	62	13	coronavirus	coronavirus	NOUN
ajlm-1282	62	14	disease	disease	NOUN
ajlm-1282	62	15	2019	2019	NUM
ajlm-1282	62	16	.	.	PUNCT
ajlm-1282	63	1	int	int	PROPN
ajlm-1282	63	2	j	j	PROPN
ajlm-1282	63	3	infect	infect	VERB
ajlm-1282	63	4	dis	dis	PROPN
ajlm-1282	63	5	.	.	PUNCT
ajlm-1282	64	1	2020;95:332–339	2020;95:332–339	PROPN
ajlm-1282	64	2	.	.	PUNCT
ajlm-1282	65	1	https://doi.org/10.1016/j.ijid.2020.04.041	https://doi.org/10.1016/j.ijid.2020.04.041	NOUN
ajlm-1282	65	2	qin	qin	PROPN
ajlm-1282	66	1	c	c	NOUN
ajlm-1282	66	2	,	,	PUNCT
ajlm-1282	66	3	zhou	zhou	PROPN
ajlm-1282	66	4	l	l	PROPN
ajlm-1282	66	5	,	,	PUNCT
ajlm-1282	66	6	hu	hu	PROPN
ajlm-1282	67	1	z	z	X
ajlm-1282	67	2	,	,	PUNCT
ajlm-1282	67	3	et	et	PROPN
ajlm-1282	67	4	al	al	PROPN
ajlm-1282	67	5	.	.	PROPN
ajlm-1282	67	6	dysregulation	dysregulation	NOUN
ajlm-1282	67	7	of	of	ADP
ajlm-1282	67	8	immune	immune	ADJ
ajlm-1282	67	9	response	response	NOUN
ajlm-1282	67	10	in	in	ADP
ajlm-1282	67	11	patients	patient	NOUN
ajlm-1282	67	12	with	with	ADP
ajlm-1282	67	13	covid-19	covid-19	PROPN
ajlm-1282	67	14	in	in	ADP
ajlm-1282	67	15	wuhan	wuhan	PROPN
ajlm-1282	67	16	,	,	PUNCT
ajlm-1282	67	17	china	china	PROPN
ajlm-1282	67	18	.	.	PUNCT
ajlm-1282	68	1	clin	clin	PROPN
ajlm-1282	68	2	infect	infect	PROPN
ajlm-1282	68	3	dis	dis	PROPN
ajlm-1282	68	4	.	.	PUNCT
ajlm-1282	69	1	2020	2020	NUM
ajlm-1282	69	2	.	.	PUNCT
ajlm-1282	70	1	https://doi.org/10.1093/cid/ciaa248	https://doi.org/10.1093/cid/ciaa248	PROPN
ajlm-1282	70	2	tan	tan	PROPN
ajlm-1282	70	3	l	l	PROPN
ajlm-1282	70	4	,	,	PUNCT
ajlm-1282	70	5	wang	wang	PROPN
ajlm-1282	70	6	q	q	PROPN
ajlm-1282	70	7	,	,	PUNCT
ajlm-1282	70	8	zhang	zhang	PROPN
ajlm-1282	70	9	d	d	PROPN
ajlm-1282	70	10	,	,	PUNCT
ajlm-1282	70	11	et	et	PROPN
ajlm-1282	70	12	al	al	PROPN
ajlm-1282	70	13	.	.	PROPN
ajlm-1282	70	14	lymphopenia	lymphopenia	PROPN
ajlm-1282	70	15	predicts	predict	NOUN
ajlm-1282	70	16	disease	disease	NOUN
ajlm-1282	70	17	severity	severity	NOUN
ajlm-1282	70	18	of	of	ADP
ajlm-1282	70	19	covid-19	covid-19	PROPN
ajlm-1282	70	20	:	:	PUNCT
ajlm-1282	70	21	a	a	DET
ajlm-1282	70	22	descriptive	descriptive	ADJ
ajlm-1282	70	23	and	and	CCONJ
ajlm-1282	70	24	predictive	predictive	ADJ
ajlm-1282	70	25	study	study	NOUN
ajlm-1282	70	26	.	.	PUNCT
ajlm-1282	71	1	signal	signal	PROPN
ajlm-1282	71	2	transduct	transduct	NOUN
ajlm-1282	71	3	target	target	NOUN
ajlm-1282	71	4	ther	ther	ADV
ajlm-1282	71	5	.	.	PUNCT
ajlm-1282	72	1	2020;5(1):33	2020;5(1):33	NUM
ajlm-1282	72	2	.	.	PUNCT
ajlm-1282	72	3	https://doi.org/10.1038/s41392-020-0159-1	https://doi.org/10.1038/s41392-020-0159-1	PROPN
ajlm-1282	73	1	xu	xu	PROPN
ajlm-1282	74	1	h	h	PROPN
ajlm-1282	74	2	,	,	PUNCT
ajlm-1282	74	3	zhong	zhong	PROPN
ajlm-1282	74	4	l	l	PROPN
ajlm-1282	74	5	,	,	PUNCT
ajlm-1282	74	6	deng	deng	PROPN
ajlm-1282	74	7	j	j	PROPN
ajlm-1282	74	8	,	,	PUNCT
ajlm-1282	74	9	et	et	PROPN
ajlm-1282	74	10	al	al	PROPN
ajlm-1282	74	11	.	.	PROPN
ajlm-1282	75	1	high	high	ADJ
ajlm-1282	75	2	expression	expression	NOUN
ajlm-1282	75	3	of	of	ADP
ajlm-1282	75	4	ace2	ace2	NOUN
ajlm-1282	75	5	receptor	receptor	NOUN
ajlm-1282	75	6	of	of	ADP
ajlm-1282	75	7	2019	2019	NUM
ajlm-1282	75	8	-	-	PUNCT
ajlm-1282	75	9	ncov	ncov	ADV
ajlm-1282	75	10	on	on	ADP
ajlm-1282	75	11	the	the	DET
ajlm-1282	75	12	epithelial	epithelial	ADJ
ajlm-1282	75	13	cells	cell	NOUN
ajlm-1282	75	14	of	of	ADP
ajlm-1282	75	15	oral	oral	ADJ
ajlm-1282	75	16	mucosa	mucosa	NOUN
ajlm-1282	75	17	.	.	PUNCT
ajlm-1282	76	1	int	int	PROPN
ajlm-1282	76	2	j	j	PROPN
ajlm-1282	76	3	oral	oral	PROPN
ajlm-1282	76	4	sci	sci	PROPN
ajlm-1282	76	5	.	.	PUNCT
ajlm-1282	77	1	2020;12:8	2020;12:8	NUM
ajlm-1282	77	2	.	.	PUNCT
ajlm-1282	78	1	https://doi.org/10.1038/s41368-020-0074-x	https://doi.org/10.1038/s41368-020-0074-x	PROPN
ajlm-1282	78	2	chen	chen	PROPN
ajlm-1282	78	3	g	g	PROPN
ajlm-1282	78	4	,	,	PUNCT
ajlm-1282	78	5	wu	wu	PROPN
ajlm-1282	78	6	d	d	PROPN
ajlm-1282	78	7	,	,	PUNCT
ajlm-1282	78	8	guo	guo	PROPN
ajlm-1282	78	9	w	w	PROPN
ajlm-1282	78	10	,	,	PUNCT
ajlm-1282	78	11	et	et	PROPN
ajlm-1282	78	12	al	al	PROPN
ajlm-1282	78	13	.	.	PROPN
ajlm-1282	79	1	clinical	clinical	ADJ
ajlm-1282	79	2	and	and	CCONJ
ajlm-1282	79	3	immunologic	immunologic	ADJ
ajlm-1282	79	4	features	feature	NOUN
ajlm-1282	79	5	in	in	ADP
ajlm-1282	79	6	severe	severe	ADJ
ajlm-1282	79	7	and	and	CCONJ
ajlm-1282	79	8	moderate	moderate	ADJ
ajlm-1282	79	9	coronavirus	coronavirus	NOUN
ajlm-1282	79	10	disease	disease	NOUN
ajlm-1282	79	11	2019	2019	NUM
ajlm-1282	79	12	.	.	PUNCT
ajlm-1282	80	1	j	j	PROPN
ajlm-1282	80	2	clin	clin	PROPN
ajlm-1282	80	3	invest	invest	VERB
ajlm-1282	80	4	.	.	PUNCT
ajlm-1282	81	1	2020;130(5):2620–2629	2020;130(5):2620–2629	NUM
ajlm-1282	81	2	.	.	PUNCT
ajlm-1282	82	1	https://doi.org/10.1172/jci137244	https://doi.org/10.1172/jci137244	PROPN
ajlm-1282	82	2	medeiros	medeiros	PROPN
ajlm-1282	82	3	ni	ni	PROPN
ajlm-1282	82	4	,	,	PUNCT
ajlm-1282	82	5	gomes	gomes	PROPN
ajlm-1282	82	6	jas	jas	PROPN
ajlm-1282	82	7	.	.	PROPN
ajlm-1282	82	8	cytometric	cytometric	PROPN
ajlm-1282	82	9	bead	bead	PROPN
ajlm-1282	82	10	array	array	NOUN
ajlm-1282	83	1	[	[	X
ajlm-1282	83	2	cba	cba	X
ajlm-1282	83	3	]	]	PUNCT
ajlm-1282	83	4	for	for	ADP
ajlm-1282	83	5	measuring	measure	VERB
ajlm-1282	83	6	cytokine	cytokine	NOUN
ajlm-1282	83	7	levels	level	NOUN
ajlm-1282	83	8	in	in	ADP
ajlm-1282	83	9	chagas	chagas	NOUN
ajlm-1282	83	10	disease	disease	NOUN
ajlm-1282	83	11	patients	patient	NOUN
ajlm-1282	83	12	.	.	PUNCT
ajlm-1282	84	1	methods	method	NOUN
ajlm-1282	84	2	mol	mol	ADP
ajlm-1282	84	3	biol	biol	PROPN
ajlm-1282	84	4	.	.	PUNCT
ajlm-1282	85	1	2019;1955:309–314	2019;1955:309–314	NUM
ajlm-1282	85	2	.	.	PUNCT
ajlm-1282	86	1	https://doi.org/10.1007/978-1-4939-9148-8_23	https://doi.org/10.1007/978-1-4939-9148-8_23	NOUN
ajlm-1282	87	1	brough	brough	PROPN
ajlm-1282	87	2	h	h	PROPN
ajlm-1282	87	3	-	-	PUNCT
ajlm-1282	87	4	a	a	NOUN
ajlm-1282	87	5	,	,	PUNCT
ajlm-1282	87	6	kalayci	kalayci	NOUN
ajlm-1282	87	7	o	o	NOUN
ajlm-1282	87	8	,	,	PUNCT
ajlm-1282	87	9	sediva	sediva	PROPN
ajlm-1282	87	10	a	a	X
ajlm-1282	87	11	,	,	PUNCT
ajlm-1282	87	12	et	et	PROPN
ajlm-1282	87	13	al	al	PROPN
ajlm-1282	87	14	.	.	PUNCT
ajlm-1282	87	15	managing	manage	VERB
ajlm-1282	87	16	childhood	childhood	NOUN
ajlm-1282	87	17	allergies	allergy	NOUN
ajlm-1282	87	18	and	and	CCONJ
ajlm-1282	87	19	immunodeficiencies	immunodeficiency	NOUN
ajlm-1282	87	20	during	during	ADP
ajlm-1282	87	21	respiratory	respiratory	ADJ
ajlm-1282	87	22	virus	virus	NOUN
ajlm-1282	87	23	epidemics	epidemic	NOUN
ajlm-1282	87	24	–	–	PUNCT
ajlm-1282	87	25	the	the	DET
ajlm-1282	87	26	2020	2020	NUM
ajlm-1282	87	27	covid-19	covid-19	PROPN
ajlm-1282	87	28	pandemic	pandemic	NOUN
ajlm-1282	87	29	.	.	PUNCT
ajlm-1282	88	1	pediatr	pediatr	PROPN
ajlm-1282	88	2	allergy	allergy	PROPN
ajlm-1282	88	3	immunol	immunol	NOUN
ajlm-1282	88	4	.	.	PUNCT
ajlm-1282	89	1	2020;31(5):442–448	2020;31(5):442–448	X
ajlm-1282	89	2	.	.	X
ajlm-1282	90	1	https://doi.org/10.1111/pai.13262	https://doi.org/10.1111/pai.13262	NOUN